WO2008008502A1 - 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication - Google Patents

4-amino-4-oxobutanoyl peptides as inhibitors of viral replication Download PDF

Info

Publication number
WO2008008502A1
WO2008008502A1 PCT/US2007/016018 US2007016018W WO2008008502A1 WO 2008008502 A1 WO2008008502 A1 WO 2008008502A1 US 2007016018 W US2007016018 W US 2007016018W WO 2008008502 A1 WO2008008502 A1 WO 2008008502A1
Authority
WO
Grant status
Application
Patent type
Prior art keywords
ci
alkyl
compound
salt
halogen
Prior art date
Application number
PCT/US2007/016018
Other languages
French (fr)
Inventor
Avinash Phadke
Xiangzhu Wang
Suoming Zhang
Atul Agarwal
Original Assignee
Achillion Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06008Dipeptides with the first amino acid being neutral
    • C07K5/06078Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06139Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06Dipeptides
    • C07K5/06191Dipeptides containing heteroatoms different from O, S, or N
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08Tripeptides
    • C07K5/0802Tripeptides with the first amino acid being neutral
    • C07K5/0804Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12Cyclic peptides with only normal peptide bonds in the ring
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Abstract

The invention rovides 4-amino-4-oxobutanoyl peptide compounds of Formula I (I) and the pharmaceutically salts and hydrates thereof. The variables R1-R9, R16, R18 R19, n, M,, n, M,, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/ or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

Description

PATENT APPLICATION IN THE UNITED STATES PATENT OFFICE

4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION

INVENTORS: Avinash Phadke,.Xiangzhu Wang, Suoming Zhang

Assignee:

Achillion Pharmaceuticals, Inc.

300 George St.

New Haven, CT 06511

Agent: Leslie-Anne Horvath Cantor Colburn LLP 55 Griffin Road S. Bloomfield, CT 06002 (860) 286-2929

CROSS REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority from U.S. provisional patent application nos. 60/830,488, filed July 13, 2006 and 60/945,786, filed June 22, 2007, both of which are hereby incorporated by reference in their entirety.

FIELD OF THE INVENTION

[0002] The present invention provides 4-amino-4-oxobutanoyl peptides, useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptides disclosed herein are potent and/ or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptides and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide as the only active agent or may contain a combination of a 4-amino-4-oxobutanoyl peptide or related compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

BACKGROUND

[0002] An estimated 3% of the world's population is infected with the hepatitis C virus. Of those exposed to HCV, 80% become chronically infected, at least 30 % develop cirrhosis of the liver and 1-4% develop hepatocellular carcinoma. Hepatitis C Virus (HCV) is one of the most prevalent causes of chronic liver disease in the United States, reportedly accounting for about 15 percent of acute viral hepatitis, 60 to 70 percent of chronic hepatitis, and up to 50 percent of cirrhosis, end-stage liver disease, and liver cancer. Chronic HCV infection is the most common cause of liver transplantation in the U.S., Australia, and most of Europe. Hepatitis C causes an estimated 10,000 to 12,000 deaths annually in the United States. While the acute phase of HCV infection is usually associated with mild symptoms, some evidence suggests that only about 15% to 20% of infected people will clear HCV.

[0003] HCV is an enveloped, single-stranded RNA virus that contains a positive-stranded genome of about 9.6 kb. HCV is classified as a member of the Hepacivirus genus of the family Flaviviridae. At least 4 strains of HCV, GT-I - GT-4, have been characterized. [0004] The HCV Hfecycle includes entry into host cells; translation of the HCV genome, polyprotein processing, and replicase complex assembly; RNA replication, and virion assembly and release. Translation of the HCV RNA genome yields a more than 3000 amino acid long polyprotein that is processed by at least two cellular and two viral proteases. The HCV polyprotein is:

NH2-C-E1-E2-P7-NS2-NS3-NS4A-NS4B-NS5A-NS5B-COOH.

[0005] The cellular signal peptidase and signal peptide peptidase have been reported to be responsible for cleavage of the N-terminal third of the polyprotein (C-El-E2-p7) from the nonstructural proteins (NS2-NS3-NS4A-NS4B-NS5A-NS5B). The NS2-NS3 protease mediates a first cis cleavage at the NS2-NS3 site. The NS3-NS4A protease then mediates a second cis- cleavage at the NS3-NS4 A junction. The NS3-NS4A complex then cleaves at three downstream sites to separate the remaining nonstructural proteins. Accurate processing of the polyprotein is asserted to be essential for forming an active HCV replicase complex.

[0006] Once the polyprotein has been cleaved, the replicase complex comprising at least the NS3-NS5B nonstructural proteins assembles. The replicase complex is cytoplasmic and membrane-associated. Major enzymatic activities in the replicase complex include serine protease activity and NTPase helicase activity in N S3, and RNA-dependent RNA polymerase activity of NS5B. In the RNA replication process, a complementary negative strand copy of the genomic RNA is produced. The negative strand copy is used as a template to synthesize additional positive strand genomic RNAs that may participate in translation, replication, packaging, or any combination thereof to produce progeny virus. Assembly of a functional replicase complex has been described as a component of the HCV replication mechanism. Provisional application 60/669,872 "Pharmaceutical Compositions and Methods of Inhibiting HCV Replication" filed April 11, 2005, is hereby incorporated by reference in its entirety for its disclosure related to assembly of the replicase complex.

[0007] Current treatment of hepatitis C infection typically includes administration of an interferon, such as pegylated interferon (IFN), in combination with ribavirin. The success of current therapies as measured by sustained virologic response (SVR) depends on the strain of HCV with which the patient is infected and the patient's adherence to the treatment regimen. Only 50% of patients infected with HCV strain GT-I exhibit a sustained virological response. Direct acting antiviral agents such as ACH-806, VX-950 and NM 283 (prodrug of NM 107) are in clinical development for treatment of chronic HCV. Due to lack of effective therapies for treatment for certain HCV strains and the high mutation rate of HCV, new therapies are needed. The present invention fulfills this need and provides additional advantages, which are described herein.

SUMMARY OF THE INVENTION

[0008] The invention provides compounds of Formula I (shown below) and includes 4- amino-4-oxobutanoyl peptides and related compounds. Certain 4-amino-4-oxobutanoyl peptides disclosed herein possess antiviral activity. The invention provides compounds of Formula I that are potent and/ or selective inhibitors of Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more compound of Formula I, or a salt, solvate, or acylated prodrug of such compounds, and one or more pharmaceutically acceptable carriers, excipients, or diluents.

[0009] The invention further comprises methods of treating patients suffering from certain infectious diseases by providing to such patients an amount of a compound of Formula I effective to reduce signs or symptoms of the disease or disorder. These infectious diseases include viral infections, particularly HCV infections. The invention particularly includes methods of treating human patients suffering from an infectious disease, but also encompasses methods of treating other animals, including livestock and domesticated companion animals, suffering from an infectious disease.

[0010] Methods of treatment include providing a compound of Formula I as a single active agent or providing a compound of Formula I in combination with one or more other therapeutic agents.

[0011] Thus in a first aspect the invention includes compounds of Formula I pharmaceutically acceptable salts thereof:

Figure imgf000007_0001
(Formula I)

[0012] Within Formula I the variables, e.g. Ri-R9, Ri6> Ri8, R.9, M, Y, Z, and n, carry the definitions set forth below.

[0013] represents a double or single covalent bond, and the group

Figure imgf000007_0002
0 or 1 double bonds.

[0014] R1 is -NRi0Rn, -(0O)NRi0Rn, -(C=S)NR10RiI5 -(C=O)R,2, -SO2R12, - (C=O)ORi2, -0(C=O)Ri2, -ORi2, Or-N(C=O)Ri2, and R2 is hydrogen, Ci-C6alkyl, C3- Cycycloalkyl, heterocycloalkyl, (aryl)Co-C4alkyl.

[0015] Or, R1 and R2 are taken together to form an optionally substituted 5- to 7- membered heterocyclic ring containing 0 or 1 additional N, S, or O atoms, or an optionally substituted 5- to 7-membered heterocyclic ring containing 0 or 1 additional N, S, or O atoms fused to an optionally substituted 5- to 7-membered carbocyclic or heterocyclic ring.

[0016] R3, R4, Rs, Re, R7, and R8 are independently

(a) hydrogen, halogen, or amino, or

(b) Ci-C6alkyl, C2-C6alkenyl, (C3-C7cycloalkyl)C0-C4alkyl, (C3-C7cycloalkenyl)C0- C4alkyl, (heterocycloalkyl)Co-C4alkyl, C2-C6alkanoyl, or mono- or di- Ci-Cβalkylamino, each of which is optionally substituted.

[0017] R3 and R4 may be joined to form an optionally substituted 3- to 7- membered cycloalkyl ring or an optionally substituted 3- to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O. [0018] R-5 and R$ may be joined to form an optionally substituted 3- to 7- membered cycloalkyl ring or an optionally substituted 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O.

[0019] R7 and Rg may be joined to form an optionally substituted 3- to 7- membered cycloalkyl ring or an optionally substituted 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O.

[0020] Rs is a C7-Cn saturated or unsaturated hydrocarbon chain that is (i) covalently bound to R7, where R7 is a methylene group or R5 is a C7-Cn saturated or unsaturated hydrocarbon chain that is (ii) covalently bound to an optionally substituted cycloalkyl ring formed by R7 and Rg being joined to from a 3- to 7- membered optionally substituted cycloalkyl ring; and Re is hydrogen, Ci-Cβalkyl, or (C3-C7cycloaIkyl)Co-C2alkyl;.

[0021] T is a tetrazole group attached via its carbon atom, or T is a group of the formula:

[.0022] Where, R9 is hydroxyl, amino, -COOH, -NRI0RH, -OR12, -SR12,

Figure imgf000008_0001
-NR10SO2R11, -NRIOSONRΠR12, -NR10SO2NRnR12, -(C=O)OR10, -NR10(C=O)ORn, or - CONR10Ri 1, Or R9 is Ci-C6alkyl, C2-C6alkenyl, C2-C6alkanoyl, (C3-C7cycloalkyl)Co-C4alkyl, (C3-C7cycloalkenyl)C0-C4alkyl, (C3-C7cycloalkyl)CH2SO2-, (C3-C7CyClOaIkVl)CH2SO2NR10-, (heterocycloalkyl)Co-C4alkyl, (aryl)C0-C2aIkyl, or (5- to 10-membered heteroaryl)Co-C2alkyl, each of which is optionally substituted.

[0023] Or, R9 is a phosphonate of the formula

Figure imgf000008_0002
where p is 0, 1 , or 2.

[0024] Or, R9 is RχXC0-C4alkyl-, where X is -(C=O)NH-, -NH(C=O)- and Rx is aryl or heteroaryl, OrR9 is -CH(Rγ)(C3-C7cycloalkyl), -SO2CH(Rγ)(C3-C7cycloalkyl), or- NRioS02CH(Rγ)(C3-C7cycloalkyl), where Rγ is halogen or Rγ is Ci-C6alkyl, C2-C6alkanoyl, (C3-C7cycloalkyl)Co-C4alkyl, (C4-C7cycloalkenyl)C0-C4alkyl, (aryl)C0-C4alkyl, (aryl)C0- C4alkoxy, (heterocycloalkyl)Co-C2alkyl, or (5- to 10-membered heteroaryl)Co-C4alkyl, each of which is optionally substituted.

[0025] Rio, Rn, and Ri2 are independently at each occurrence hydrogen, or Ci-Cβalkyl, C2-C6alkenyl, Qj-Cealkynyl, (aryl)C0-C2alkyl, (C3-C7cycloalkyl)Co-C2alkyl, (C3- C7cycloalkenyl)Co-C2alkyl, (heterocycloalkyl)Co-C2alkyl, or (5- to 10-membered heteroaryl)Co- C2alkyl, each of which is optionally substituted.

[0026] Ri3 is hydrogen or Ci-C2alkyl.

[0027] RH and Ri5 are independently hydrogen, hydroxyl, or Ci-C2alkyl.

[0028] n is 0, 1, or 2.

[0029] M is hydrogen, halogen, hydroxyl, Ci-C2alkyl, or Ci-C2alkoxy.

[0030] Y is absent, CRi8Ri9, NR20, S, O, -0(C=O)(NR20)-, NH(C=0)(NR2o)-, NH(S=O)(NR2O)-, or -O(C=O)-; or Y is taken together with one of J, L, or M to form a ring.

[0031] J is CH2 or J is taken together with Y to form a 3- to 7- membered carbocyclic or heterocyclic ring, which ring is substituted with 0 or 1 or more substituents independently chosen from halogen, hydroxy, amino, cyano, Ci-C2alkyl, Ci-C2alkoxy, Ci-C2alkoxy, trifluoromethyl, and trifluoromethoxy; when J is taken together with Y to form a ring Z may be absent.

[0032] L is CH2 or L is taken together with Y to form a 3- to 7- membered cafbocyclic or heterocyclic ring, which ring is substituted with 0 or 1 or more substituents independently chosen from halogen, hydroxy, amino, cyano, Ci-C2alkyl, Ci-C2alkoxy, Ci-C2alkoxy, trifluoromethyl, and trifluoromethoxy; when L is taken together with Y to form a ring Z may be absent.

[0033] Z is (mono- or bicyclic aryl)Co-C2alkyl or (mono- or bicyclic heteroaryl)Co- C2alkyl, each of which Z is substituted with 0 or 1 or more substituenis independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, -SO2NRnRn, -(C=O)NRnRi2, - NRn(C=O)Ri2, Ci-C4alkyl, C2-C4alkanoyl, Ci-C4alkoxy, CrC4alkylthio, mono- and di-Ci- C4alkylamino, Ci-C4alkylester, Ci-Chaloalkyl, and Ci-C2haloalkoxy, and 0 or 1 (C3- C7cycloalkyl)CoC2alkyl, (phenyl)C0-C2alkyl, (phenyl)Co-C2alkoxy, (5- or 6-membered heteroaryl)Co-C2alkyl5 (5- or 6-membered heteroaryl)Co-C2alkoxy, naphthyl, indanyl, (5- or 6- membered heterocycloalkyI)Co-C2alkyl, or 9- or 10-membered bicyclic heteroaryl, each of which is substituted with 0, 1, or 2 substituents independently chosen from: (c) halogen, hydroxyl, amino, cyano, nitro, -COOH, -CONH2, CH3(C=O)NH-, =NOH, Ci-C4alkyl, Ci-C4alkoxy, Ci-C4hydroxyalkyl> mono- and di-C1-C4alkylamino, -NRgSOiRn, - C(O)ORn, -NR8CORn, -NR8C(O)ORn, trifluoromethyl, and trifluoromethoxy, and

(d) phenyl and 5- or 6-membered heteroaryl, each of which is substituted with O or 1 or more of halogen, hydroxyl, Ci-C4alkyl, and Ci-C2alkoxy.

[0034] R]6 represents 0 to 4 substituents is independently chosen at from halogen, Ci- C∑alkyl, and Ci-C2alkoxy.

[0035] Rig and R19 are independently hydrogen, hydroxyl, halogen, Ci-C2alkyl, Ci- C∑alkoxy, Ci-C2haloalkyl, or Ci-C2haloalkoxy.

[0036] R2O is hydrogen, Ci-C2alkyl, Ci-C2haloalkyl, or Ci-C2haloalkoxy.

[0037] Certain compounds of Formula I disclosed herein exhibit good activity in an HCV replication assay, such as the HCV replicon assay set forth in Example 3, which follows. Preferred compounds of Formula I exhibit an EC50 of about 40 micromolar or less, or more preferably an EC50 of about 10 micromolar or less; or still more preferably an EC50 of about 5 nanomolar or less in an HCV replicon replication assay

DETAILED DESCRIPTION OF THE INVENTION CHEMICAL DESCRIPTION AND TERMINOLOGY

[0038] Prior to setting forth the invention in detail, it may be helpful to provide definitions of certain terms to be used herein. Compounds of the present invention are described using standard nomenclature. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs. Unless clearly contraindicated by the context each compound name includes the free acid or free base form of the compound as well hydrates of the compound and all pharmaceutically acceptable salts of the compound.

[0039] The term "4-amino-4-oxobutanoyl peptides " encompasses all compounds that satisfy Formula I, including any enantiomers, racemates and stereoisomers, as well as all pharmaceutically acceptable salts of such compounds. The phrase "a compound of Formula I" includes all forms of such compounds, including salts and hydrates, unless clearly contraindicated by the context in which this phrase is used. [0040] The terms "a" and "an" do not denote a limitation of quantity, but rather denote the presence of at least one of the referenced item. The term "or" means "and/or". The terms "comprising", "having", "including", and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not Limited to"). Recitation of ranges of values are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. The endpoints of all ranges are included within the range and independently combinable. All methods described herein can be performed in a suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., "such as"), is intended merely to better illustrate the invention and does not pose a limitation on the scope of the invention unless otherwise claimed. No language in the specification should be construed as indicating any non-claimed element as essential to the practice of the invention as used herein. Unless defined otherwise, technical and scientific terms used herein have the same meaning as is commonly understood by one of skill in the art to which this invention belongs.

[0041] An "active agent" means a compound (including a compound of the invention), element, or mixture that when administered to a patient, alone or in combination with another compound, element, or mixture, confers, directly or indirectly, a physiological effect on the patient. The indirect physiological effect may occur via a metabolite or other indirect mechanism. When the active agent is a compound, then salts, solvates (including hydrates) of the free compound, crystalline forms, non-crystalline forms, and any polymorphs of the compound are included. Compounds may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g., asymmetric carbon atoms, so that the compounds can exist in different stereoisomer^ forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds can additionally be mixtures of diastereomers. For compounds having asymmetric centers, all optical isomers in pure form and mixtures thereof are encompassed. In addition, compounds with carbon-carbon double bonds may occur in Z- and E-forms, with all isomeric forms of the compounds. In these situations, the single enantiomers, i.e., optically active forms can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by resolution of the racemates. Resolution of the racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral HPLC column. All forms are contemplated herein regardless of the methods used to obtain them.

[0042] A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -(CKyCs-Cβcycloalkyl is attached through carbon of the methylene (CH2) group.

[0043] "Alkanoyl" indicates an alkyl group as defined herein, attached through a keto (- (C=O)-) bridge. Alkanoyl groups have the indicated number of carbon atoms, with the carbon of the keto group being included in the numbered carbon atoms. For example a C2alkanoyl group is an acetyl group having the formula CHs(C=O)-.

[0044] A bond represented by a combination of a solid and dashed line, ie. , may be either a single or double bond.

[0045] "Alkyl" is a branched or straight chain saturated aliphatic hydrocarbon group, having the specified number of carbon atoms, generally from 1 to about 12 carbon atoms. The term Ci-Cgalkyl as used herein indicates an alkyl group having from 1 to about 6 carbon atoms. Other embodiments include alkyl groups having from 1 to 8 carbon atoms, 1 to 4 carbon atoms or from 1 to 2 carbon atoms, e.g. Ci-Csalkyl, Ci-C4alkyl, and Ci-C2alkyl. When Co-Cn alkyl is used herein in conjunction with another group, for example, (aryl)Co-C4 alkyl, the indicated group, in this case aryl, is either directly bound by a single covalent bond (Co), or attached by an alkyl chain having the specified number of carbon atoms, in this case from 1 to about 4 carbon atoms. Co~Cnalkyl is used in conjunction with heteroaryl, aryl, phenyl, cycloalkyl, and heterocycloalkyl, e.g,, (5- to 10-membered heteroaryl)Co-C2alkyl, (aryl)Co-C2alkyl, (phenyl)Co- C2alkyl, (C3-C7cycloalkyl)Co-C4alkyl, and (heterocycloalkyl)Co-C4alkyl. Examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, 3-methylbutyl, t-butyl, n-pentyl, and sec-pentyl.

[0046] "Alkenyl" indicates a straight or branched hydrocarbon chain comprising one or more unsaturated carbon- carbon double bonds, which may occur in any stable point along the chain. Alkenyl groups described herein have the indicated number of carbon atoms. E.g. C2- Cβalkenyi indicates an alkenyl group of from 2 to about 6 carbon atoms. When no number of carbon atoms is indicated, alkenyl groups described herein typically have from 2 to about 12 carbon atoms, though lower alkenyl groups, having 8 or fewer carbon atoms, are preferred. Examples of alkenyl groups include ethenyl, propenyl, and butenyl groups.

[0047] "Alkynyl" indicates a straight or branched hydrocarbon chain comprising one or more carbon-carbon triple bonds, which may occur in any stable point along the chain. Alkenyl groups described herein have the indicated number of carbon atoms. E.g. C2-C6alkynyl indicates an alkynyl group of from 2 to about 6 carbon atoms. When no number of carbon atoms is indicated, alkynyl groups described herein typically have from 2 to about 12 carbon atoms, though lower alkynyl groups, having 8 or fewer carbon atoms, are preferred.

[0048] "Alkoxy" indicates ah alkyl group as defined above with the indicated number of carbon atoms attached through an oxygen bridge (-O-). Examples of alkoxy include, but are not limited to, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, 2-butoxy, t-butoxy, n-pentoxy, 2- pentoxy, 3- pentoxy, isopentoxy, neopentoxy, n-hexoxy, 2-hexoxy, 3-hexoxy, and 3- methylpentoxy. When "Co-Qialkoxy" is used in with another group, for example, (heteroaryl)Co-C4 alkoxy, the indicated group, in this case heteroaryl, is either attached via a covalently bound oxygen bridge (Coalkoxy), or attached by an alkoxy group having the specified number of carbon atoms, in this case from 1 to about 4 carbon atoms, that is covalently bound to the group it substitutes via the alkoxy oxygen atom.

[0049] The term "alkylester" indicates an alkyl group as defined herein attached through an ester linkage. The ester linkage may be in either orientation, e.g. a group of the formula -O(C=O)alkyl or a group of the formula -(C=O)Oalkyl.

[0050] "Alkylthio" means alkyl-S-, where the alkyl group is an alkyl group as defined herein having the indicated number of carbon atoms and the point of attachment of the alkythio substituent is on the sulfur atom. An exemplary alkylthio group is methylthio.

[0051] "Aryl" indicates an aromatic group containing only carbon in the aromatic ring or rings. Such aromatic groups may be further substituted with carbon or non-carbon atoms or groups. Typical aryl groups contain 1 or 2 separate, fused, or pendant rings and from 6 to about 12 ring atoms, without heteroatoms as ring members. Where indicated aryl groups may be substituted. Such substitution may include fusion to a 5 to 7-membered saturated cyclic group that optionally contains 1 or 2 heteroatoms independently chosen from N, O, and S, to form, for example, a 3,4-methylenedioxy-phenyl group. Aryl groups include, for example, phenyl, naphthyl, including 1-naphthyl and 2-naρhthyl, and bi-phenyl. [0052] In the term "(aryl)alkyl," aryl and alkyl are as defined above, and the point of attachment is on the alkyl group. "(Aryl)Co-C4alkyl" indicates an aryl group that is directly attached via a single covalent bond (aryl)Coalkyl or attached through an alkyl group having from 1 to about 4 carbon atoms. Examples of (aryl)alkyl groups include piperonyl and (phenyl)alkyl groups such as benzyl and phenylethyl. Similarly, the term "(aryl)Co-C4alkoxy" indicates an aryl group that is directly attached to the molecule it substitutes via an oxygen bridge, e.g. (aryl)Coalkoxy, or covalently bound to an alkoxy group having from 1 to 4 carbon atoms.

[0053] A "carbocyclic ring" is a saturated, partially unsaturated, or aromatic cyclic group containing only carbon ring atoms. A "5- to 7-membered carbocyclic ring" has from 5 to 7 carbon ring atoms. Unless otherwise indicated, the carbocyclic ring may be attached to its pendant group at any carbon atom that results in a stable structure. When indicated the carbocyclic rings described herein may be substituted on any available ring carbon if the resulting compound is stable. Carbocyclic rings include, cycloalkyl groups, such as cyclopropyl and cyclohexyl; cycloalkenyl groups, such as cyclohexenyl, bridged cycloalkyl groups; and aryl groups, such as phenyl.

[0054] "Cycloalkyl" saturated hydrocarbon ring group, having the specified number of carbon atoms. Monocyclic cycloalkyl groups typically have from 3 to about 8 carbon ring atoms or from 3 to about 7 carbon ring atoms. Cycloalkyl substituents may be pendant from a substituted nitrogen or carbon atom, or a substituted carbon atom that may have two substituents may have a cycloalkyl group, which is attached as a spiro group. Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, or cyclohexyl as well as bridged or caged saturated ring groups such as norbornane or adamantane. Likewise "cycloalkenyl" is a hydrocarbon ring group having the indicated number of carbon atoms and at least carbon-carbon double between ring carbon atoms.

[0055] The terms "(cycloalkyl)Co-Cnalkyl" and "(cycloalkenyl) Co-Cnalkyl" indicate a substituent in which the cycloalkyl or cycloalkenyl and alkyl are as defined herein, and the point of attachment of the (cycloalkyl)alkyl group or (cycloalkenyl)alkyl group to the molecule it substitutes is either a single covalent bond, (Coalkyl) or on the alkyl group. (Cycloalkyl)alkyl encompasses, but is not limited to, cyclopropylmethyl, cyclohexylmethyl, and cyclohexylmethyl.

[0056] "Haloalkyl" indicates both branched and straight-chain alkyl groups having the specified number of carbon atoms, substituted with 1 or more halogen atoms, up to the maximum allowable number of halogen atoms. Examples of haloalkyl include, but are not limited to, trifiuoromethyl, difluoromethyl, 2-fluoroethyl, and penta-fluoroethyl.

[0057] "Haloalkoxy" indicates a haloalkyl group as defined herein attached through an oxygen bridge (oxygen of an alcohol radical).

[0058] "Halo" or "halogen" indicates any of fluoro, chloro, bromo, and iodo.

[0059] "Heteroaryl" indicates a stable monocyclic aromatic ring having the indicated number of ring atoms which contains from 1 to 3, or in some embodiments from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a stable bicyclic or tricyclic system containing at least one 5- to 7-membered aromatic ring which contains from 1 to 3, or in some embodiments from 1 to 2, heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon. Monocyclic heteroaryl groups typically have from 5 to 7 ring atoms. In some embodiments bicyclic heteroaryl groups are 9- to 10-membered heteroaryl groups, that is, groups containing 9 or 10 ring atoms in which one 5- to 7-member aromatic ring is fused to a second aromatic or non-aromatic ring. "Tricyclic heteroaryl" groups contain three fused rings, at least one of which is a heteroaryl ring. When the total number of S and O atoms in the heteroaryl group exceeds 1 , these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heteroaryl group is not more than 2. It is particularly preferred that the total number of S and O atoms in the aromatic heterocycle is not more than 1. Examples of heteroaryl groups include, but are not limited to, oxazolyl, pyranyl, pyrazinyl, pyrazolopyrimidinyl, pyrazolyl, pyridizinyl, pyridyl, pyrimidinyl, pyrrolyl, quinolinyl, tetrazolyl, thiazolyl, thienylpyrazolyl, thiophenyl, triazolyl, benzotcTjoxazolyl, benzofuranyl, benzothiazolyl, benzothiophenyl, benzoxadiazolyl, dihydrobenzodioxynyl, furanyl, imidazolyl, • indolyl, and isoxazolyl.

[0060] The term "heterocycloalkyl" indicates a saturated monocyclic group having the indicated number of ring atoms and containing from 1 to about 3 heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or a saturated bicyclic ring system having at least one N, O, or S ring atom with the remaining atoms being carbon. Monocyclic heterocycloalkyl groups usually have from 4 to about 8 ring atoms. In some embodiments monocyclic heterocyloalkyl groups have from 5 to 7 ring atoms. Bicyclic heterocycloalkyl groups typically have from about five to about 12 ring atoms. Examples of heterocycloalkyl groups include morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl groups. [0061] The term "(heterocycloalkyl)alkyl" indicates a saturated substituent in which the heterocycloalkyl and alkyl are as defined herein, and the point of attachment of the (heterocycloalkyl)alkyl group to the molecule it substitutes is on the alkyl group. This term encompasses, but is not limited to, piperidylmethyl, piperazinylmethyl, and pyrrolidinylmethyl.

[0062] The term "heterocyclic ring" indicates a saturated, partially unsaturated, or aromatic cyclic group having the indicated number of ring atoms, typically from 5 to 8 ring atoms, and containing from 1 to about 4 heteroatoms chosen from N, O, and S, with remaining ring atoms being carbon, or bicyclic saturated, partially unsaturated, or aromatic heterocylic or tricyclic ring system, containing at least 1 heteroatom in the multiple ring system chosen from N, O, and S and containing up to about 4 heteroatoms independently chosen from N, O, and S in each ring of the multiple ring system. Bicyclic and tricyclic rings have the indicated number of ring atoms with bicyclic heterocyclic ring systems typically having from 7 to 11 ring atoms and tricyclic systems from 10 to 15 ring atoms. Examples of heterocyclic groups include, pyridyl, indolyl, pyrimidinyl, pyridizinyl, pyrazinyl, imidazolyl, oxazolyl, furanyl, thiophenyl, thiazolyl, triazolyl, tetrazolyl, isoxazolyl, quinolinyl, pyrrolyl, pyrazolyl, benz[&]thiophenyl, isoquinolinyl, quinazolinyl, quinoxalinyl, thienyl, isoindolyl, dihydroisoindolyl, 5,6,7,8-tetrahydroisoquinoline, pyridinyl, pyrimidinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, and pyrrolidinyl.

[0063] Additional examples of heterocyclic groups include, but are not limited to 1,1- dioxo-thieno-tetrahydrothiopyranyl, 1,1-dioxothiochromanyl, 1,4-dioxanyl, 5-pteridmyl, tetrahydroindazolyl, azetidinyl, benzimidazolyl, benzisoxazinyl, benzodioxanyl, benzodioxolyl, benzofurazanyl, benzoisoxolyl, benzopyranyl, benzopyrazolyl, benzotetrahydrofuranyl, benzotetrahydrothienyl, benzothiopyranyl, benzotriazolyl, benzoxazinyl, benzoxazolinonyl, benzoxazolyl, beta-carbolinyl, carbazolyl, carbolinyl, chromanonyl, chromanyl, cinnolinyl, coumarinyl, dihydroazetidinyl, dihydrobenzisothiazinyl, dihydrobenzisoxazinyl, dihydrobenzodioxinyl, dihydrobenzofuranyl, dihydrobenzoimidazolyl, dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrocoumarinyl, dihydroindolyl, dihydroisocoumarinyl, dihydroisooxazolyl, dihydroisoquinolinonyl, dihydroisothiazolyl, dihydrooxadiazolyl, dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl, dihydropyrirQidinyl, dihydropyrrolyl, dihydroquinolinonyl, dihydroquinolinyl, dihydrotetrazolyl, dihydrotMadiazolyl, dihydrothiazolyl, dihydrothienyl, dihydrotriazolyl, hexahydroazepinyl, imidazopyrazinyl, imidazopyridazinyl, imidazopyridinyl, imidazopyridyl, imidazopyrimidinyl, imidazothiadiazolyl, imidazothiazolyl, imidazothiophenyl, indolinyl, indolizinyl, isobenzotetrahydrofuranyl, isobenzotetrahydrothienyl, isobenzotbienyl, isochromanyl, isocoumarinyl, isoindolinonyl, isoindolinyl, isoquinolyl, isotbiazolyl, isoxazolyl, methylenedioxybenzyl. naphthyridinyl, oxadiazolyl, oxazolopyridinyl, oxazolyl, oxetanyl, oxopiperidinyl, oxopyrazolyl, oxopyridinyl, phenotbiazinyl, phenoxazinyl, phthalazinyl, purinyl, pyrazinyl, pyrazolopyrazinyl, pyrazolopyridazinyl, pyrazolopyridyl, pyrazolopyrimidinyl, pyrazolothiophenyl, pyrazolotriazinyl, pyridazinyl, pyridopyridinyl, quinazolinyl, quinolinyl, quinoxalinyl, tetrahydrofuranyl, tetrahydroimidazopyrazinyl, tetrahydroinύdazopyridazuiyl, tetrahydroimidazopyridinyl, tetrahydroimidazopyrimidyl, tetrahydroisoquinolinyl, tetrahydropyranyl, tetrahydropyrazolopyrazinyl, tetrahydropyrazolopyridinyl, tetrahydropyrazolopyrimidyl, tetrahydroquinolinyl, tetrahydrothienyl, tetrahydrotriazolopyrimidyl, tetrahydrotriazolopyrazinyl, tetrahydrotriazolopyridazinyl, tetrahydrotriazopyridinyl, tetrazolopyridyl, tetrazolyl, thiadiazolyl, thieno-tetrahydrotbiopyranyl, thienyl, thiochromanyl, triazinyl, triazolopyraziByl, triazolopyridazinyl, triazolopyridyl, triazolopyrimidinyl, triazolothiophenyl, and where possible, N-oxides thereof.

[0064] "Hydroxyalkyl" is an alkyl group having the indicated number of carbon atoms and substituted with at least one hydroxyl substituent. Where indicated, the hydroxyalkyl group may be further substituted.

[0065] The term "mono- and/ or di-alkylamino" indicates secondary or tertiary alkyl amino groups, wherein the alkyl groups are independently chosen alkyl groups, as defined herein, having the indicated number of carbon atoms. The point of attachment of the alkylamino group is on the nitrogen. Examples of mono- and di-alkylamino groups include ethylamino, dimethylamino, and methyl-propyl-amino.

[0066] "Mono- and/ or di-alkylcarboxamide" indicates a mono-alkylcarboxamide group of formula (alkyl I)-NH-(C=O)- or a dialkylcarboxamide group of the formula (alkyl I)(alkyl2)- N-(C=O)- in which the point of attachment of the mono- or dialkylcarboxamide substituent to the molecule it substitutes is on the carbon of the carbonyl group. The term "mono and/ or dialkylcarboxamide" also includes groups of the formula (alkyl I)(C=O)NH- and (alkyl I)(C=O) (alkyl2)N- in which the point of attachment is the nitrogen atom. The groups alkyl 1 and alkyl2 are independently chosen alkyl groups having the indicated number of carbon atoms. [0067] "Oxo," means a keto group (C=O). An oxo group that is a substituent of a nonaromatic carbon atom results in a conversion Of-CH2- to — C(=O)-. An oxo group that is a substituent of an aromatic carbon atom results in a conversion of -CH- to -C(=O)- and a loss of aromaticity.

[0068] The term "substituted", as used herein, means that any one or more hydrogens on the designated atom or group is replaced with a selection from the indicated group, provided that the designated atom's normal valence is not exceeded. When the substituent is oxo (i.e., =O) then 2 hydrogens on the atom are replaced. When an oxo group substitutes aromatic moieties, the corresponding partially unsaturated ring replaces the aromatic ring. For example a pyridyl group substituted by oxό is a pyridone. Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds or useful synthetic intermediates. A stable compound or stable structure is meant to imply a compound that is sufficiently robust to survive isolation from a reaction mixture, and subsequent formulation into an effective therapeutic agent. Unless otherwise specified substituents are named into the core structure. For example, it is to be understood that when (cycloalkyl)alkyl is listed as a possible substituent the point of attachment of this substituent to the core structure is in the alkyl portion.

[0069] Suitable groups that may be present on a "substituted" position include, but are not limited to, e.g., halogen; cyano; hydroxyl; nitro; azido; alkanoyl (such as a C2-C6 alkanoyl group such as acyl or the like); carboxamido; alkyl groups (including cycloalkyl groups, having 1 to about 8 carbon atoms, or 1 to about 6 carbon atoms); alkenyl and alkynyl groups (including groups having one or more unsaturated linkages and from 2 to about 8, or 2 to about 6 carbon atoms); alkoxy groups having one or inore oxygen linkages and from 1 to about 8, or from 1 to about 6 carbon atoms; aryloxy such as phenoxy; alkylthio groups including those having one or more thioether linkages and from 1 to about 8 carbon atoms; or from 1 to about 6 carbon atoms; alkylsulfmyl groups including those having one or more sulfϊnyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; alkylsulfonyl groups including those having one or more sulfonyl linkages and from 1 to about 8 carbon atoms, or from 1 to about 6 carbon atoms; aminoalkyl groups including groups having one or more N atoms and from 1 to about 8, or from 1 to about 6 carbon atoms; aryl having 6 or more carbons and one or more rings, (e.g., phenyl, biphenyl, naphthyl, or the like, each ring either substituted or unsubstituted aromatic); arylalkyl having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyl being an exemplary arylalkyl group; arylalkoxy having 1 to 3 separate or fused rings and from 6 to about 18 ring carbon atoms, with benzyloxy being an exemplary arylalkoxy group; or a saturated, unsaturated, or aromatic heterocyclic group having 1 to 3 separate or fused rings with 3 to about 8 members per ring and one or more N, O or S atoms, e.g. coumarinyl, quinolinyl, isoquinolmyl, quinazolinyl, pyridyl, pyrazinyl, pyrimidinyl, furanyl, pyrrolyl, thienyl, thiazolyl, triazinyl, oxazolyl, isoxazolyl, imidazolyl, indolyl, benzofuranyl, benzothiazolyi, tetrahydrofuranyl, tetrahydropyranyl, piperidinyl, moφholinyl, piperazinyl, and pyrrolidinyl. Such heterocyclic groups may be further substituted, e.g. with hydroxy, alkyl, alkoxy, halogen and amino.

[0070] A "vinyl" group is a substituent of the formula 1HC=.

[0071] A "dosage form" means a unit of administration of an active agent. Examples of dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, creams, ointments, suppositories, inhalable forms, transdermal forms, and the like.

[0072] "Pharmaceutical compositions" are compositions comprising at least one active agent, such as a compound or salt of Formula I, and at least one other substance, such as a carrier, excipient, or diluent. Pharmaceutical compositions meet the U.S. FDA's GMP (good manufacturing practice) standards for human or non-human drugs.

[0073] "Pharmaceutically acceptable salts" includes derivatives of the disclosed compounds in which the parent compound is modified by making inorganic and organic, nontoxic, acid or base addition salts thereof. The salts of the present compounds can be synthesized from a parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting free acid forms of these compounds with a stoichiometric amount of the appropriate base (such as Na, Ca, Mg, or K hydroxide, carbonate, bicarbonate, or the like), or by reacting free base forms of these compounds with a stoichiometric amount of the appropriate acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. Generally, non-aqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred, where practicable. Salts of the present compounds further include solvates of the compounds and of the compound salts.

[0074] Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. The pharmaceutically acceptable salts include the conventional non-toxic salts and the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. For example, conventional nontoxic acid salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, nitric and the like; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, mesylic, esylic, besylic, sulfanilic, 2-acetoxybenzoic, fumaric, toluenesulfonic, methanesulfonic, ethane disulfonic, oxalic, isethionic, HOOC-(CEk)-1-COOH where n is 0-4, and the like. Lists of additional suitable salts may be found, e.g., in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).

[0075] The term "carrier" applied to pharmaceutical compositions of the invention refers to a diluent, excipient, or vehicle with which an active compound is provided.

[0076] A "pharmaceutically acceptable excipient" means an excipient that is useful in preparing a pharmaceutical composition that is generally safe, non-toxic and neither biologically nor otherwise undesirable, and includes an excipient that is acceptable for veterinary use as well as human pharmaceutical use. A "pharmaceutically acceptable excipient" as used in the present application includes both one and more than one such excipient.

[0077] A "patient" is a human or non-human animal in need of medical treatment. Medical treatment can include treatment of an existing condition, such as a disease or disorder, prophylactic or preventative treatment, or diagnostic treatment. In some embodiments the patient is a human patient.

[0078] "Prodrug" means any compound that becomes compound of the invention when administered to a mammalian subject, e.g., upon metabolic processing of the prodrug. Examples of prodrugs include, but are not limited to, acetate, formate and benzoate and like derivatives of functional groups (such as alcohol or amine groups) in the compounds of the invention.

[0079] "Providing" means giving, administering, selling, distributing, transferring (for profit or not), manufacturing, compounding, or dispensing.

[0080] "Providing a compound of Formula I with at least one additional active agent" means the compound of Formula I and the additional active agent(s) are provided simultaneously in a single dosage form, provided concomitantly in separate dosage forms, or provided in separate dosage forms for administration separated by some amount of time that is within the time in which both the compound of Formula I and the at least one additional active agent are within the blood stream of a patient. The compound of Formula I and the additional active agent need not be prescribed for a patient by the same medical care worker. The additional active agent or agents need not require a prescription. Administration of the compound of Formula I or the at least one additional active agent can occur via any appropriate route, for example, oral tablets, oral capsules, oral liquids, inhalation, injection, suppositories or topical contact.

[0081] "Treatment," as used herein includes providing a compound of Formula I and at least one additional active agent sufficient to: (a) prevent a disease or a symptom of a disease from occurring in a patient who may be predisposed to the disease but has not yet been diagnosed as having it (e.g. including diseases that may be associated with or caused by a primary disease (as in liver fibrosis that can result in the context of chronic HCV infection); (b) inhibiting the disease, i.e. arresting its development; and (c) relieving the disease, i.e., causing regression of the disease. "Treating" and "treatment" also means providing a therapeutically effective amount of a compound of Formula I and at least one additional active agent to a patient having or susceptible to a hepatitis C infection.

[0082] A "therapeutically effective amount" of a pharmaceutical combination of this invention means an amount effective, when administered to a patient, to provide a therapeutic benefit such as an amelioration of symptoms, e.g., an amount effective to decrease the symptoms of a hepatitis C infection. For example a patient infected with a hepatitis C virus may present elevated levels of certain liver enzymes, including AST and ALT. Normal levels of AST are from 5 to 40 units per liter of serum (the liquid part of the blood) and normal levels of ALT are from 7 to 56 units per liter of serum. A therapeutically effect amount is thus an amount sufficient to provide a significant reduction in elevated AST and ALT levels or an amount sufficient to provide a return of AST and ALT levels to the normal range. A therapeutically effective amount is also an amount sufficient to prevent a significant increase or significantly reduce the detectable level of virus or viral antibodies in the patient's blood, serum, or tissues. One method of determining treatment efficacy includes measuring HCV RNA levels by a convention method for determining viral RNA levels such as the Roch TaqMan assay. In certain preferred embodiments treatment reduces HCV RNA levels below the

[0083] the limit of quantitation (30 IU/mL, as measured by the Roche TaqMan(R) assay) or more preferably below the limit of detection (10 IU/mL, Roche TaqMan). [0084] A significant increase or reduction in the detectable level of virus or viral antibodies is any detectable change that is statistically significant in a standard parametric test of statistical significance such as Student's T-test, where p < 0.05.

[0085] CHEMICAL DESCRIPTION

[0086] Formula I includes all subformulae thereof. In certain situations, the compounds of Formula I may contain one or more asymmetric elements such as stereogenic centers, stereogenic axes and the like, e.g. asymmetric carbon atoms, so that the compounds can exist in different stereoisomers forms. These compounds can be, for example, racemates or optically active forms. For compounds with two or more asymmetric elements, these compounds can additionally be mixtures of diastereomers. For compounds having asymmetric centers, it should be understood that all of the optical isomers and mixtures thereof are encompassed. In addition, compounds with carbon-carbon double bonds may occur in Z- and E-forms, with all isomeric forms of the compounds being included in the present invention. In these situations, single enantiomers, i.e., optically active forms, can be obtained by asymmetric synthesis, synthesis from optically pure precursors, or by resolution of the racemates. Resolution of the racemates can also be accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example using a chiral HPLC column.

[0087] Where a compound exists in various tautomeric forms, the invention is not limited to any one of the specific tautomers, but rather includes all tautomeric forms.

[0088] The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but different mass numbers. By way of general example, and without limitation, isotopes of hydrogen include tritium and deuterium and isotopes of carbon include 11C, 13C, and 14C.

[0089] Certain compounds are described herein using a general formula that includes variables, e.g. R1-R9, R1.6, Ri8» Ri9> n, M, Y, and Z. Unless otherwise specified, each variable within such a formula is defined independently of other variables. Thus, if a group is said to be substituted, e.g. with 0-2 R*, then the group may be substituted with up to two R* groups and R* at each occurrence is selected independently from the definition of R*. Also, combinations of substituents and/or variables are permissible only if such combinations result in stable compounds. [0090] In addition to compounds of Formula I as described above, the invention also includes compounds of Formula I in which one or more of the following conditions is met for the variables R1-R9, Ri 6, Ris, R19, n, M, Y, and Z. The invention includes compounds of Formula I that carry any combination of the variable definitions set forth below that results in a stable compound.

2

Figure imgf000023_0001

The Ri and Rz variables

[0091] In certain embodiments the variables R1 and R2 carry one of the definitions set forth below.

[0092] (1) (2) R1 and R2 are joined to form a 5- to 7- membered heterocyloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, O, and which ring is optionally fused to a 5- or 6-membered heteroaryl group (e. g. phenyl or pyridyl) to form a bicyclic ring system, each of which 5- to 7- membered heterocycloalkyl ring is optionally substituted.

[0093] (2) R1 and R2 are joined to form a pyrrolidine, piperidine, orpiperazine ring or a piperazine ring fused to a phenyl, each of which is optionally substituted with 0 to 3 substituents independently chosen from A- and AB- where A is halogen, hydroxyl, amino, cyano, -CONH2, - COOH, 0!-043IkVl, C2-C4alkanoyl, Ci-C4aUcoxy, Ci-C4alkylthio, mono- or di-Ci-C4alkylamino, Ci-C4alkylester, C1-C4alkylesteramine, mono- or di-Ci-C4alleylcarboxamide,

Figure imgf000023_0002
or Ci-C2haloalkoxy; and B is Ci-C4alkyl.

[0094] (2) Ri and R2 are joined to form a pyrrolidine, piperidine, or piperazine ring or a piperazine ring fused to a phenyl, each of which is optionally substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, amino, CONH2, -COOH, Ci-C2alkyl, and Q- Caalkoxy.

[0095] (3) R1 is C1-C4O(C=O)-, Ci-C4(C=O)-

Figure imgf000024_0001

[0096] (4) R2 is Cj-Cβalkyl or C3-C7cycloalkyl.

[0097] (5) R2 is hydrogen. The variables R3 to R8

[0098] In certain embodiments the variables R3 to Rg carry one of the definitions set forth below.

[0099] (1) R3, R4, R5, R6, R7, and R8 are independently (a) hydrogen, or (b) C]-C4alkyl or (C3-C7cycloalkyl)Co-C4alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2- C4alkanoyl, Ci-C4alkoxy, Ci^C4alkylthio, mono- and di-Ci-C4alkylamino, Ci-Cshaloalkyl, and Ci-Chaloalkoxy.

[00100] (2) R3, R4, Rs, Re, R-7, and R8 are independently hydrogen, C1-C4Bl-CyI, or

(C3-C7cycloalkyl)Co-C4alkyl.

[0100] (3) R3, R4, R5, Re, R7, and R8 are independently hydrogen or methyl.

[0101] (4) Any of R3 and R4 and/ or R5 and Re, and/ or R7 and Rg are joined to form a 3- to 7- membered cycloalkyl ring or 3- to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O, each of which ring, is substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, amino, cyano, vinyl, Ci-C∑alkyl, Ci- C2alkoxy, trifluoromethyl, and trifluoromethoxy.

[0102] (5) Any OfR3 and R4 and/ or R5 and Rg, and/ or R7 and R8 are joined to form a 3- to 7- membered cycloalkyl ring or 5- to 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O, each of which ring is substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-C2alkoxy.

[0103] (6) R3, R4, and Rg, are independently hydrogen or methyl;

R5 is Ci-Cβalkyl, C2-C6alkenyl, (C3-C7cycloalkyl)Co-C4alkyl, (C3-C7cycloalkenyl)Co- C4alkyl, (heterocycloalkyl)Co-C4alkyl, C2-C6alkanoyl, or mono- or di- Ci-Cβalkylamino; and

R7 and Rg are joined to form an optionally substituted 3- to 7- membered cycloalkyl ring or an optionally substituted 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N5 S, and O.

[0104] (7) R5 is Ci-Cealkyl or (C3-C7cycloalkyl)C0-C4alkyl; and R7 and R8 are joined to form a cyclopropyl ring, which is unsubstituted or substituted with 1 or 2 Ci-Cβalkyl or C2- Cβalkenyl.

[0105] (8) The invention includes compounds in which R3 and R4 are hydrogen, R5 is hydrogen, R_s is t-butyl, and R7 and Rg are joined to form a cyclopropyl group substituted by a vinyl group. For example the invention includes compounds of Formula II

Figure imgf000026_0001
(Formula II)

[0106] (9) R.3, R4, Re, and Re are independently hydrogen or methyl; and Rs is a C7-C11 saturated or unsaturated hydrocarbon chain that is covalently bound to R7, where R7 is a methylene group. For example the invention includes compound of Formula III

Figure imgf000026_0002
(Formula III) where D is an alkyl or alkenyl group having 6 to 10 carbon atoms.

[0107] (10) The invention also includes compounds in which R3 and R4 are both hydrogen, and R5 is covalently bound to R7 via an 8-membered mono-unsaturated hydrocarbon chain. For Example in the invention includes compounds of Formula (IV)

Figure imgf000026_0003
(Formula IV). [0108] (11) R.3, R4, and R6 are independently hydrogen or methyl; and R.5 is a CyC π saturated or unsaturated hydrocarbon chain that is covalently bound to an optionally substituted cycloalkyl ring formed by R? and Re being joined to from a 3- to 7- membered optionally substituted cycloalkyl ring. For example the invention includes compounds and salts of Formula V

Figure imgf000027_0001
(Formula V) where D is an alkyl or alkenyl group having 6 to 10 carbon atoms.

[0109] (12) The invention also includes compounds and salts in which R3 and R4 are both hydrogen and R5 is a 7-carbon mono-unsaturated hydrocarbon chain that is covalently bound to a substituted cycloalkyl ring formed by R7 and Rg. For example the invention includes compounds and salts of Formula VI and VI-A:

Figure imgf000027_0002

Figure imgf000028_0001
(Formula VI-A). The Rg variable

[0110] In certain embodiments the R9 variable carries one of the definitions set forth below.

[0111] (1) T is a group of the formula ' R9 and R9 is hydroxyl, amino, -COOH, -

Figure imgf000028_0002

-NR10SO2R11, -NR10SONR11R12, -NR10SO2NRnRi2, -(C=O)OR10,

Figure imgf000028_0003
or -CONRioRii-

[0112] (2) R9 is hyάϊoxyl, aiiiino, -COOH, -NR10Rn, -OR12, -NRI0SO2RI 1, - (C=O)OR]0, or -CONRioRπ.

[Ol 13] (3) R9 is Ci-Cealkyl, C2-C6alkenyl, C2-C6alkanoyl, (C3-C7cycloalkyl)C0-C4alkyl, (C3-C7cycloalkenyl)Co-C4alkyl, (heterocycloalkyl)C0-C4alkyl, (aryl)C0-C2alkyl, or (5- to 10- membered heteroaτyl)C0-C2alkyl, each of which is substituted with O or 1 or more substituents independently chosen from halogen, hydroxyl, amino, cyano, oxo -COOH, -CONH2, oxo, Ci-C4alkyl,

Figure imgf000028_0004
C2-C4alkanoyl, Ci-C4alkylthio, mono- and di- Ci- C4alkylamino, Ci-C4alkylester, mono- and di- C1-C4alkylcarboxamide, Ci-C2haloalkyl, and Ci- Cahaloalkoxy.

[Ol 14] (4) R9 is Ci-Cβalkyl, C2-C6alkenyl, C2-C6alkanoyl, (C3-C7cycloalkyl)Co-C4allcyl, (C3-C7cycloalkenyl)Co-C4a]kyl, (heterocycloalkyl)C0-C4alkyl, (aryl)C0-C2alkyl, or (5- to 10- membered heteroaryl)Co-C2alkyl each of which is substituted with O or 1 or more substituents independently chosen from halogen, hydroxyl, amino, cyano, oxo -COOH, -CONH2, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-Ci-C4alkylamino, Ci-C2haloaLkyl, and Ci- C2haloalkoxy. [0115] (5) R-9 is a phosphonate of the formula

Figure imgf000029_0001
where p is 1 or 2 and Rj3-RiS carry the values set forth in the "Summary of the Invention" section.

[0116] (6) R9 is RχXCi-C4alkyl-, where X is -(C=O)NH-, -NH(C=O)- and Rx is phenyl or pyridyl.

[0117] (7) R9 is -CH(Rγ)(C3-C7cycloalkyl), -SO2CH(RY)(C3-C7cycloalkyl), or -NR102CH(Rγ)(C3-C7cycloalkyl), where Rγ is halogen, or Rγ is Ci-C2alkyl, C2-C6alkanoyl, (C3-C7cycloalkyl)Co-C2alkyl, (phenyl)Co-C4alkyl, (phenyl)Co-C4alkoxy, (heterocycloalkyl)Co- C2alkyl, or (5- to 10-membered heteroaryl)Co-C4alkyl, each of which is substituted with 0 or 1 or more substituents independently chosen from halogen; hydroxy!, amino, cyano, oxo -COOH, -CONH2, oxo, Ci-C4alkyl, Ci-G^alkoxy, mono- and di-Ci-C4alkylamino, C1-C2haloalkyl, and Ci- C2haloalkoxy.

[0118] (8) R9 is — NR10SO2R11.. In some embodiments Rio is hydrogen or methyl and Rn is cyclopropyl. The Rio, Ru, and R12 variables

[0119] In any of the above definitions of R9 the variables Rio, Rn, and Rn may carry the definition set forth for Formula I in the "Summary of the Invention" section. Rj 0, Rn, and R12 may also carry any of definitions that follow.

[0120] (1) Rio, Rn, and Ri2 are independently Ci-C6alkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)Co-C4alkyl, (heterocycloalkyl)C0-C4alkyl:, (phenyl)C0-C2alkyl, (naphthyl)C0- C∑alkyl, or (5- to 10-membered heteroaryl)Co-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, amino, cyano, oxo -COOH, -CONH2) oxo, Ci-C4alkyl, Ci-C4alkoxy, C2-C4alkanoyl, Ci-C4alkylthio, mono- and di- Ci-C4alkylamino, Ci-C4alkylester, mono- and di- Ci-C4alkylcarboxamide, Ci-C2haloalkyl, and Ci-C2haloalkoxy.

[0121] (2) Rio, Rn, and Ri2 are independently hydrogen, or Ci-Cβalkyl, C2-C6alkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)Co-C2alkyl, (heterocycloalkyl)Co-C2alkyl, (phenyl)C0-C2alkyl, or (5- to 6-membered monocyclic heteroaryl)Co-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, oxo, Ci-C2alkyl, Ci-C2alkoxy, trifluoromethyl, and trifluoromethoxy. [0122] (3) Rio, Rn, and Rj2 are independently hydrogen or Ci-Cβalkyl. The Y, M, J, L, and Z variables

[0121] The invention includes compounds and salts of Formulae I to VI in which Y, M, and Z carry the variables set forth below. Y, M, and Z include the variables n, Ri 8, and R19.

[0122] (1) Y is absent, CH2, O, or -0(C=O)- and n is 0.

[0123] (2) Y is O and n is 0.

[0124] (3) Y is absent, CH2, O, or -O(C=O)-, and Ri8 and RJ9 are independently hydrogen or methyl, and n is 1.

[0125] (4) The invention includes compounds and salts in which n is 1.

[0126] (5) M is hydrogen.

[0127] (6) J and L are both CH2.

[0128] (7) Z is 1-naphthyl, 2-napthyl,

Figure imgf000030_0001
Figure imgf000031_0001

Figure imgf000031_0003

Figure imgf000031_0004

Figure imgf000031_0006

Figure imgf000031_0007
Figure imgf000031_0002

Figure imgf000031_0008
Figure imgf000031_0005
Figure imgf000031_0009
Figure imgf000032_0001

[0129] (8) Z is a group of the formula

Figure imgf000032_0002

[0130] Within the above chemical formula X1-X5, G1-G4, and R21-R24 carry the following definitions.

[0131] Xi, X2, X3, X4, and X5 are independently N or CH and no more than two of Xj - X5 are N.

[0132] G], G2, G3, and G4 are independently CH2, O, S, orNR.24, wherein no more than two OfG1 to G4 are other than hydrogen. [0133] R2. represents from 0 to 3 groups independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl, Ci-C4alkoxy, Ci-C4alkylthio, mono- and di-Ci-C4alkylamino, Ci-C2haloalkyl, and Ci-Cahaloalkoxy.

[0134] R.22 is hydrogen, halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl, Ci-C4allcoxy, Ci-C4alkylthio, mono- and di-CrC4alkylamino, Ci-C4alkylester, Ci-Cahaloalkyl, and Ci-C2haloalkoxy, or

[0135] R22 is (C3-C7cycloalkyl)Co-C2alkyl, (phenyl)Co-C2alkyl, (phenyl)C0-C2alkoxy, (5- or 6-membered heteroaryl)Co-C2alkyl, (5- or 6-membered heteroaryl)Co-C2alkoxy, naphthyl, indanyl, (5- or 6-membered heterocycloalkyl)Co-C2alkyl, or 9- or 10 membered bicyclic heteroaryl, each of which is substituted with 0, 1, or 2 substituents independently chosen from

(c) halogen, hydroxyl, amino, cyano, nitro, -COOH, -CONH2, CH3(C=O)NH-, Cx- C4alkyl, Ci-C4alkoxy, Ci-C4hydroxyalkyl, mono- and di-Ci-C4alkylamino, -NRSSO2RH, -C(O)ORu, -NR8CORn, -NR8C(O)ORu, trifluoromeiliyl, trifluoromethoxy, and

(d) phenyl and 5- or 6-membered heteroaryl, each of which is substituted with 0 or 1 or more of halogen, hydroxyl, Ci-C4alkyl, Ci-C2alkoxy.

[0136] R23 is 0 to 2 substituents independently chosen from halogen, hydroxyl, Ci- C2alkyl, and Ci-C2alkoxy.

[0137] R24 is independently chosen at each occurrence from hydrogen and Ci-C2alkyl. [0138] In certain embodiments R22 is

Figure imgf000033_0001
Figure imgf000034_0001

[0139] (9) Z is a group of the formula

Figure imgf000034_0002

[0140] Within this embodiment X1-X5 and R21 -R23 carry the following definitions.

[0141] Xi, X2, X3, and X4, are independently N or CH and no more than two of X1-X4 are N.

[0142] R21 represents from 0 to 3 groups independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl,- C2-C4alkanoyl, Ci-C4alJcoxy, Cj-C4alkylthio, mono- and di-Ci-C4alkylamino, Ci-C2haloalkyl, and Ci-C2haloalkoxy.

[0143] R22 is hydrogen, halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl, 0!-043IkOXy, Ci-C4alkylthio, mono- and di-Ci-C4alkylamino, C1 -C4alkyl ester, Ci-C2haloalkyl, and Ci-C2haloalkoxy.

[0144] Or, R22 is (C3-C7cycloalkyl)CoC2alkyl, (phenyl)C0-C2alkyl, (phenyl)C0-C2alkoxy, (5- or 6-membered heteroaryl)Co-C2alkyl, (5- or 6-membered heteroaryl)Co-C2alkoxy, naphthyl, indanyl, (5- or 6-membered heterocycloalkyl)CoC2alkyl, or 9- or 10 membered bicyclic heteroaryl, each of which is substituted with 0, 1, or 2 substituents independently chosen from

(c) halogen, hydroxyl, amino, cyano, nitro, -COOH, -CONH2, CH3(C=O)NH-, Ci- C4alkyl, Ci-C4alkoxy, Ci-C4hydroxyalkyls mono- and di-Ci-C4aIkylamino, -NR8SO2Rn5 - C(O)ORn, -NR8CORn3 -NR8C(O)ORn, trifluoromethyl, and trifluoromethoxy, and

(d) phenyl and 5- or 6-membered heteroaryl, each of which is substituted with 0 or 1 or more of halogen, hydroxyl, Ci^alkyl, Ci-C2alkoxy.

[0145] (10) Z is a group of the formula

Figure imgf000035_0001
wherein X1-X5 and R21-R22 carry the definitions set forth for embodiment

(7), immediately above.

[0146] (9) Z is a quinoline of the formula

Figure imgf000035_0002
wherein Xi-Xs and R21-R22 carry the definitions set forth for embodiment (7).

[0147] Or in certain embodiments, R21 represents a substituent at the 7-position of the quinoline, and 0 to 2 additional substituents independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl, Ci-C4alkoxy, mono- and di-Ci- C4alkylamino, Ci-C2haloalkyl, and Ci-C2haloalkoxy; and R22 is (phenyl)Co -C2alkyl or (pyridyl)Co-C2alkyl, each of which is substituted with 0, 1, or 2 substituents independently chosen from halogen, hydroxyl, amino, cyano, -COOH, -CONH2, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-Ci-C4alkylamino, trifluoromethyl, and trifluoromethoxy.

[0148] (10) The invention includes compounds and salts wherein n is 0, Z is absent, and Y and M are taken together to form a ring, so that

Figure imgf000036_0001
is a group for the formula:

Figure imgf000036_0002

Within this embodiment Gi, G2, G3, G4, and G5 are independently CH2, O, S, or NR22; wherein no more than two of Gi, G2, G3, G4, and G5 are other than CH2.

[0149] R21 is 0 to 2 substituents independently chosen from halogen, hydroxy, Cj- C2alkyl, and Ci-C2alkoxy;

[0150] R22 is independently chosen at each occurrence from hydrogen and methyl; and

[0151] R23 is 0 to 2 substituents independently chosen from halogen, hydroxy, Q- Calkyl, and Ci-C2alkoxy.

(11) The invention includes compounds and salts in which n is 0, M is hydrogen, Z is absent, and Y and J are taken together to form a ring, so that

Figure imgf000036_0003
is a group for the formula:
Figure imgf000037_0001

Within this embodiment Gi, G2, G3, and G4 are independently CH2, O, S, or NR22; wherein no more than two of Gi, G2, G3, and G4 are other than CH2.

[0152] R21 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci- C2alkyl, and Ci-C∑alkoxy;

[0153] R22 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci- C2alkyl, and Ci-C2alkoxy; and

[0154] R23 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci- C2alkyl, and Ci-C2alkoxy.

[0155] (12) The invention further includes compounds and salts of wherein

Figure imgf000037_0002
is a group for the formula: ~3o* O~V jt- ~>_i- H ~>_i-
Figure imgf000037_0003
Figure imgf000038_0001

[0156] (13) The invention includes compounds and n is 0, Z is absent, and Y and L are taken together to form a ring, so that

Figure imgf000038_0002
is a group for the formula:

Figure imgf000038_0003

[0157] Within this embodiment G], G2, G3, and G4 are independently CH2, O, S5 or NR22; wherein no more than two of Gi, G2, G3, and G4 are other than CH2.

[0158] Qi and Q2 are independently CH or N.

[0159] R21 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci- C2alkyl, and Ci-C2alkoxy;

[0160] R.22 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci- C2alkyl, and Ci-C2alkoxy; and

[0161] R-23 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci- C2alkyl, and Ci-C2alkoxy. [0162] (14) The invention includes compounds and salts wherein

Figure imgf000039_0001
is a group for the formula:
Figure imgf000039_0002

Figure imgf000040_0001

Figure imgf000041_0001

[0163] (15) The invention includes compounds and salts of Formula VII and Formula VIII in which Y is oxygen.

Figure imgf000041_0002

Formula VII

Figure imgf000041_0003

[0164] Within this embodiment:

[0165] Ri and R2 are joined to form a pyrrolidine, piperidine, or piperazine ring or a piperazine ring fused to a phenyl, each of which is optionally substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, amino, CONH2, -COOH, Ci-C2alkyl, and Cj- C2alkoxy.

[0166] R3, R4, Re, and Rg are independently chosen from hydrogen, Ci-C4alkyl, and (C3- C7cycloalkyl)Co-C2alkyl.

[0167] R9 is hydroxyl, amino, -COOH, -NR10Rn, -ORi2, -NR10SO2Rn5 -(C=O)OR]0, or -CONRioRii-

[0168] Rio.Rii, and R12 are independently hydrogen, or Ci-Csalkyl, C2-C$alkenyl, C2- CδaUcynyl, (C3-C7cycloalkyl)Co-C2alkyl, (heterocycloalkyl)C0-C2alkyl, (phenyl)C0-C2alkyl, or (5- to 6-membered monocyclic heteroaryl)Co-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, oxo, Ci-C2alkyl, Ci-C2alkoxy, trifluoromethyl, and trifluoromethoxy.

[0169] Ri6 is 0 to 2 substituents independently chosen from halogen, Ci-C2alkyl, and Ci- C∑alkoxy. [0170] M is hydrogen or methyl.

[0171] (ll) Zis a quinoline of the formula

Figure imgf000042_0001
in which,

R21 represents a substituent at the 7-position of the quinoline, and 0 to 2 additional substituents independently chosen from halogen, hydroxy., amino, cyano, -CONH2, -COOH, CrQalkyl, C2-C4alkanoyl, Ci-C4alkoxy, mono- and di-Ci-C4alkyl amino, Ci- Cihaloalkyl, and Ci-C2haloalkox.y; and

[0172] R22 is (phenyl)Co -C2alkyl or (pyridyl)Co-C2alkyl, each of which is substituted with 0, 1, or 2. substituents independently chosen from halogen, hydroxyl, amino, cyano, - COOH, -CONH2J Ci-C4alkyl, Ci-C4alkoxy, mono- and di-Ci-C4alkylamino, trifluoromethyl, and trifluoromethoxy.

PHARMACEUTICAL PREPARATIONS

[0173] Compounds of the invention can be administered as the neat chemical, but are preferably administered as a pharmaceutical composition. Accordingly, the invention provides pharmaceutical formulations comprising a compound or pharmaceutically acceptable salt of the invention, together with at least one pharmaceutically acceptable carrier.

[0174] Compounds of the invention may be administered orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as an ophthalmic solution, or by other means, in dosage unit formulations containing conventional pharmaceutically acceptable carriers. The pharmaceutical composition may be formulated as any pharmaceutically useful form, e.g., as an aerosol, a cream, a gel, a pill, a capsule, a tablet, a syrup, a transdermal patch, or an ophthalmic solution. Some dosage forms, such as tablets and capsules, are subdivided into suitably sized unit doses containing appropriate quantities of the active components, e.g., an effective amount to achieve the desired purpose.

[0175] Carriers include excipients and diluents and must be of sufficiently high purity and sufficiently low toxicity to render them suitable for administration to the patient being treated. The carrier can be inert or it can possess pharmaceutical benefits of its own. The amount of carrier employed in conjunction with the compound is sufficient to provide a practical quantity of material for administration per unit dose of the compound.

[0176] Classes of carriers include, but are not limited to binders, buffering agents, coloring agents, diluents, disintegrants, emulsifiers, flavorants, glidents, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents. Some carriers may be listed in more than1 one class, for example vegetable oil may be used as a lubricant in some formulations and a diluent in others. Exemplary pharmaceutically acceptable carriers include sugars, starches, celluloses, powdered tragacanth, malt, gelatin; talc, and vegetable oils. Optional active agents may be included in a pharmaceutical composition, which do not substantially interfere with the activity of the compound of the present invention.

[0177] Binders are substances that bind or "glue" powders together and make them cohesive by forming granules, thus serving as the "adhesive" in the formulation. Binders add cohesive strength to that already available in the diluent or bulking agent. Examples of binders include starch, gelatin, natural sugars, corn sweeteners, natural and synthetic gums such as acacia, sodium alginate, carboxymethylcellulose, polyethylene glycol and waxes. The amount of binder in the composition can range, for example, from about 2 to about 20% by weight of the composition, or from about 3 to about 10% by weight, even more preferably from about 3 to about 6% by weight.

[0178] Diluents include sugars such as lactose, sucrose, mannitol and sorbitol; starches derived from wheat, corn, rice and potato; and celluloses such as microcrystalline cellulose. The amount of diluent in the composition maybe, for example, about 10 to about 90% by weight of the total composition, about 25 to about 75%, about 30 to about 60% by weight, or about 12 to about 60%.

[0179] Disintegrants are materials added to a pharmaceutical composition to help it break apart (disintegrate) and release the active agent. Suitable disintegrants include starches; including "cold water soluble" modified starches such as sodium carboxymethyl starch; natural and synthetic gums such as locust bean, karaya, guar, and tragacanth gum and agar; cellulose derivatives such as methylcellulose and sodium carboxymethylcellulose; microcrystalline celluloses and cross-linked microcrystalline celluloses such as sodium croscarmellose; alginates such as alginic acid and sodium alginate; clays such as bentonites; and effervescent mixtures. The amount of disintegrant in the composition can range, for example, from about 2 to about 15% by weight of the composition or from about 4 to about 10% by weight.

[0180] Lubricants are substances added to a pharmaceutical formulation to enable the tablet, granules, etc. after it has been compressed, to release from the; mold or die by reducing friction or wear. Examples of lubricants useful in pharmaceutical dosage forms include boric acid, sodium benzoate, sodium acetate, sodium chloride, and the like. Lubricants are usually added at the very last step before tablet compression, since they must be present on the surfaces of the granules and in between them and the parts of the tablet press. The amount of lubricant in the composition can range, for example, from about 0.1 to about 5% by weight of the composition, from about 0.5 to about 2%, or from about 0.3 to about 1.5% by weight. The amount of compound or salt of the invention in a unit dose may be generally varied or adjusted from about 1.0 milligram to about 1,000 milligrams, from about 1.0 to about 900 milligrams, from about 1.0 to about 500 milligrams, or from about 1 to about 250 milligrams, according to the particular application and the potency of the compound. The actual dosage employed may be varied depending upon the patient's age, sex, weight and severity of the condition being treated.

[0181] Pharmaceutical compositions formulated for oral administration are often preferred. These compositions contain between 0.1 and 99% of a compound of the invention and usually at least about 5% (weight %) of a compound of the invention. Some embodiments contain from about 25% to about 50% or from 5% to 75 % of a compound of invention. Liquids formulations

[0182] Compounds of the invention can be incorporated into oral liquid preparations such as aqueous or oily suspensions, solutions, emulsions, syrups, tinctures, syrups, or elixirs, for example. Moreover, formulations containing these compounds can be presented as a dry product, e.g. as granules or powders, for constitution with water or other suitable vehicle before use. Typical components of carriers for syrups, elixirs, emulsions and suspensions include ethanol, glycerol, propylene glycol, polyethylene glycol, liquid sucrose, sorbitol and water. Liquid preparations can contain conventional additives, such as suspending agents (e.g., sorbitol syrup, methyl cellulose, glucose/sugar, syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminum stearate gel, and hydrogenated edible fats), emulsifying agents (e.g., lecithin, sorbitan monsoleate, or acacia), non-aqueous vehicles, which can include edible oils (e.g., almond oil, fractionated coconut oil, silyl esters, propylene glycol and ethyl alcohol), and preservatives (e.g., methyl or propyl p-hydroxybenzoate and sorbic acid). . Oral formulations may contain demulcent, flavoring agents, sweetening agents, such as sucrose or saccharin, taste- masking agents, and coloring agents. Suspensions

[0183] Aqueous suspensions contain the active material(s) in admixture with excipients suitable for the manufacture of aqueous suspensions. Such excipients are suspending agents, for example AVICEL RC-591, sodium carboxymethylcellulose, methylcellulose, hydropropylmethylcellulose, sodium alginate, polyvinylpyrrolidone, gum tragacanth and gum acacia; dispersing or wetting agents, for example lecithin and polysorbate 80. The aqueous suspensions may also contain one or more preservatives, for example ethyl, n- propyl p- hydroxybenzoate, methyl parabens, propyl parabens, and sodium benzoate.

[0184] Oily suspensions may be formulated by suspending the active ingredients in a vegetable oil, for example peanut oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. The oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents such as those set forth above, and flavoring agents may be added to provide palatable oral preparations. These compositions may be preserved by the addition of an anti-oxidant such as ascorbic acid. Emulsions

[0185] Pharmaceutical compositions of the invention may also be in the form of oil-in- water emulsions. The oily phase may be a vegetable oil, for example olive oil or peanut oil, or a mineral oil, for example liquid paraffin or mixtures of these. Suitable emulsifying agents may be naturally-occurring gums, for example gum acacia or gum tragacanth, naturally-occurring phosphatides, for example soy bean, lecithin, and esters or partial esters derived from fatty acids and hexitol, anhydrides, for example sorbitan monoleate, and condensation products of the said partial esters with ethylene oxide, for example polyoxyethylene sorbitan monoleate. Tablets and Capsules

[0186] Tablets typically comprise conventional pharmaceutically compatible adjuvants as inert diluents, such as calcium carbonate, sodium carbonate, mannitol, lactose and cellulose; binders such as starch, gelatin and sucrose; disintegrants such as starch, alginic acid and croscarmelose; lubricants such as magnesium stearate, stearic acid and talc. Glidants such as silicon dioxide can be used to improve flow characteristics of the powder mixture. Coloring agents, such as the FD&C dyes, can be added for appearance. Sweeteners and flavoring agents, such as aspartame, saccharin, menthol, peppermint, and fruit flavors, are useful adjuvants for chewable tablets. Capsules (including time release and sustained release formulations) typically comprise one or more solid diluents disclosed above. The selection of carrier components often depends on secondary considerations like taste, cost, and shelf stability.

[0187] Such compositions may also be coated by conventional methods, typically with pH or time-dependent coatings, such that the subject compound is released in the gastrointestinal tract in the vicinity of the desired topical application, or at various times to extend the desired action. Such dosage forms typically include, but are not limited to, one or more of cellulose acetate phthalate, polyvinylacetate phthalate, hydroxypropyl methylcellulose phthalate, ethyl cellulose, Eudragit coatings, waxes and shellac.

[0188] Formulations for oral use may also be presented as hard or soft shell capsules. A capsule is a dosage form provided in a special container or enclosure containing an active agent. The active agent may be present in solid, liquid, gel, or powder form, or any other pharmaceutically acceptable form. A capsule shell may be made of methyl cellulose, polyvinyl alcohols, or denatured gelatins or starch or other material. Hard shell capsules are typically made of blends of relatively high gel strength bone and pork skin gelatins. Soft shell capsule shells are often made of animal or plant gelatins. The capsule itself may contain small amounts of dyes, opaquing agents, plasticizers and preservatives.

[0189] The active agent in a capsule may be mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or in the case of soft gelatin capsules the active ingredient may be mixed with water or an oil medium, for example peanut oil, liquid paraffin or olive oil. Injectable and Parenteral formulations

[0190] Pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension. This suspension may be formulated according to the known art using those suitable dispersing or wetting agents and suspending agents that have been mentioned above. The sterile injectable preparation may also be sterile injectable solution or suspension in a non-toxic parentally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil may be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are useful in the preparation of injectables.

[0191] Compounds of the invention may be provided parenterally in a sterile medium. Parenteral administration includes subcutaneous injections, intravenous, intramuscular, intrathecal injection or infusion techniques. The drug, depending on the vehicle and concentration used, can either be suspended or dissolved in the vehicle. Advantageously, adjuvants such as local anesthetics, preservatives and buffering agents can be dissolved in the vehicle. In compositions for parenteral administration the carrier typically comprises least about 90% by weight of the total composition. PACKAGED FORMULATIONS

[0192] The invention includes packaged pharmaceutical combinations. Such packaged combinations include a compound of Formula I in a container. The container may additionally include instructions for using the combination to treat or prevent a viral infection, such as a hepatitis C infection, in a patient.

[0193] The packaged pharmaceutical combination may include one or more additional active agents. METHODS OF TREATMENT

[0194] The invention includes methods of preventing and treating hepatitis C infections, by providing an effective amount of a compound of the invention to patient at risk for hepatitis C infection or infected with a hepatitis C virus.

[0195] The pharmaceutical combinations disclosed herein are useful for preventing and treating hepatitis C infections in patients. An effective amount of a pharmaceutical combination of the invention may be an amount sufficient to (a) prevent hepatitis C or a symptom of a hepatitis C from occurring in a patient who may be predisposed to hepatitis C but has not yet been diagnosed as having it or prevent diseases that may be associated with or caused by a primary hepatitis C infection (such as liver fibrosis that can result in the context of chronic HCV infection); (b) inhibit the progression of hepatitis C; and (c) cause a regression of the hepatitis C infection. An amount of a pharmaceutical composition effect to inhibit the progress or cause a regression of hepatitis C includes an amount effective to stop the worsening of symptoms of hepatitis C or reduce the symptoms experienced by a patient infected with the hepatitis C virus. Alternatively a halt in progression or regression of hepatitis C may be indicated by any of several markers for the disease. For example, a lack of increase or reduction in the hepatitis C viral load or a lack of increase or reduction in the number of circulating HCV antibodies in a patient's blood are markers of a halt in progression or regression of hepatitis C infection. Other hepatitis C disease markers include aminotransferase levels, particularly levels of the liver enzymes AST and ALT. Normal levels of AST are from 5 to 40 units per liter of serum (the liquid part of the blood) and normal levels of ALT are from 7 to 56 units per liter of serum. These levels will typically be elevated in a HCV infected patient. Disease regression is usually marked by the return of AST and ALT levels to the normal range.

[0196] Symptoms of hepatitis C that may be affected by an effective amount of a pharmaceutical combination of the invention include decreased liver function, fatigue, flu-like symptoms: fever, chills, muscle aches, joint pain, and headaches, nausea, aversion to certain foods, unexplained weight loss, psychological disorders including depression, tenderness in the abdomen, and jaundice.

[0197] "Liver function" refers to a normal function of the liver, including, but not limited to, a synthetic function including synthesis of proteins such as serum proteins (e.g., albumin, clotting factors, alkaline phosphatase, aminotransferases (e.g., alanine transaminase, aspartate transaminase), 5 '-nucleosidase, y glutaminyltranspeptidase, etc.), synthesis of bilirubin, synthesis of cholesterol, and synthesis of bile acids; a liver metabolic function, including carbohydrate metabolism, amino acid and ammonia metabolism, hormone metabolism, and lipid metabolism; detoxification of exogenous drugs; and a hemodynamic function, including splanchnic and portal hemodynamics.

[0198] An effective amount of a combination described herein will also provide a sufficient concentration of the active agents in the concentration when administered to a patient. A sufficient concentration of an active agent is a concentration of the agent in the patient's body necessary to prevent or combat the infection. Such an amount may be ascertained experimentally, for example by assaying blood concentration of the agent, or .theoretically, by calculating bioavailability. The amount of an active agent sufficient to inhibit viral infection in vitro may be determined with a conventional assay for viral infectivity such as a replicon based assay, which has been described in the literature. [0199] The invention also includes using pharmaceutical combinations comprising a compound of the invention and at least one additional active agent in prophylactic therapies. In the context of prophylactic or preventative treatment an effective amount of a compound of the invention is an amount sufficient to significantly decrease the patient's risk of contracting a hepatitis C infection.

[0200] Methods of treatment include providing certain dosage amounts of a compound of the invention and the at least one additional active agent to a patient. Dosage levels of each active agent of from about 0.1 mg to about 140 mg per kilogram of body weight per day are useful in the treatment of the above- indicated conditions (about 0.5 mg to about 7 g per patient per day). The amount of active ingredient that may be combined with the carrier materials to produce a single dosage form will vary depending upon the patient treated and the particular mode of administration. Dosage unit forms will generally contain between from about 1 mg to about 500 mg of each active agent, hi certain embodiments 25 mg to 500 mg, or 25 mg to 200 mg of a compound of the invention are provided daily to a patient. When the additional active agent is NM 283 (valopicitabine), 100 mg to 1000 mg/ day, or 200 mg to 800 mg/day, or 200 to 400 mg/ day of either of those agents are typically provided to the patient. When the additional active agent is VX-950, 1000 mg to 3750 mg/ day, or 1200 mg to 1800 mg/day are administered to the patient. Treatment regiments in which VX-950 is an additional active agent and about 350 to about 450 mg or about 700 to about 800 mg of VX-950 are administered to a patient three times per day or about 350 to about 450 mg or about 700 to about 800 mg is administered every 12 hours are particularly included in the invention.

[0201] Frequency of dosage may also vary depending on the compound used and the particular disease treated. However, for treatment of most infectious disorders, a dosage regimen of 4 times daily or less is preferred and a dosage regimen of 1 or 2 times daily is particularly preferred.

[0202] It will be understood, however, that the specific dose level for any particular patient will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease undergoing therapy. COMBINATION METHODS

[0203] The invention, includes methods of treatment in which a compound or salt of the invention is provided together with one or more additional active agents. In certain embodiments the active agent (or agents) is an HCV protease inhibitor or HCV polymerase inhibitor. For example the protease inhibitor may be telaprevir (VX-950) and the polymerase inhibitor may be valopicitabine, or NM 107, the active agent which valopicitabine is converted into in vivo. In certain embodiments the second active agent is ribavirin, interferon, or Peg- interferon alpha conjugate

[0204] According to the methods of the invention, the compound of the invention and an additional active agent maybe: (1) co-formulated and administered or delivered simultaneously in a combined formulation; (2) delivered by alternation or in parallel as separate formulations; or (3) by any other combination therapy regimen known in the art. When delivered in alternation therapy, the methods of the invention may comprise administering or delivering the compound of The invention and an. additional active agent sequentially, e.g., in separate solution, emulsion, suspension, tablets, pills or capsules, or by different injections in separate syringes. In general, during alternation therapy, an effective dosage of each active ingredient is administered sequentially, i.e., serially, whereas in simultaneous therapy, effective dosages of two or more active ingredients are administered together. Various sequences of intermittent combination therapy may also be used.

[0205] In certain embodiments method of treatment includes providing a patient with a compound of Formula I and an interferon such as a pegylated interferon or interferon gamma. The interferon may be the only compound provided with the compound of the invention or may be provided with an additional active agent that is not' an interferon.

[0206] The invention methods of treatment and pharmaceutical combinations including compounds of the invention any one or combination of the following compounds and substances as an additional active agent:

Caspase inhibitors: IDN 6556 (Idun Pharmaceuticals)

Cvclophilin Inhibitors: NIM811 (Novartis) and DEBIO-025 (Debiophaπn)

Cytochrome P450 monooxygenase inhibitors: ritonavir (WO 94/14436), ketoconazole, troleandomycin, 4-methyl pyrazole, cyclosporin, clomethiazole, cimetidine, itraconazole, fluconazole, miconazole, fluvoxamine, fluoxetine, nefazodone, sertraline, indinavir, nelfinavir, amprenavir, fosamprenavir, saquinavir, lopinavir, delavirdine, erythromycin, VX-944, and VX- 497. Preferred CYP inhibitors include ritonavir, ketoconazole, troleandomycin, 4-methyl pyrazole, cyclosporin, and clomethiazole

Glucocorticoids: hydrocortisone, cortisone, prednisone, prednisolone, methylprednisolone, triamcinolone, paramethasone, betamethasone, and dexamethasone

Hematopoietins: hematopoietin-1 and hematopoietin-2. Other members of the hematopoietin superfamily such as the various colony stimulating factors (e.g. (e.g. G-CSF, GM- CSF, M-CSF), Epo, and SCF (stem cell factor)

Homeopathic Therapies: Milk Thistle, silymarin, ginseng, glycyrrhizin, licorice root, schisandra, vitamin C, vitamin E, beta carotene, and selenium

Immunomodulatory compounds: thalidomide, IL-2, hematopoietins, IMPDH inhibitors, for example Merimepodib (Vertex Pharmaceuticals Inc.), interferon, including natural interferon (such as OMNIFERON, Viragen and SUMIFERON, Sumitomo, a blend of natural interferons), natural interferon alpha (ALFERON, Hemispherx Biopharma, Inc.), interferon alpha nl from lymphblastoid cells (WELLFERON, Glaxo Wellcome), oral alpha interferon, Peg-interferon, Peg-interferon alfa 2a (PEGASYS, Roche), recombinant interferon alfa 2a (ROFERON, Roche), inhaled interferon alpha 2b (AERX, Aradigm), Peg-interferon alpha 2b (ALBUFERON, Human Genome Sciences/ Novartis, PEGINTRON, Schering), recombinant interferon alfa 2b (INTRON A, Schering), pegylated interferon alfa 2b (PEG-INTRON, Schering, VIRAFERONPEG, Schering) interferon beta- Ia (REBIF, Serono, Inc. and Pfizer), consensus interferon alpha (INFERGEN, Valeant Pharmaceutical), interferon gamma-lb (ACTIMMUNE, Intermune, Inc.), un-pegylated interferon alpha, alpha interferon, and its analogs, and synthetic thymosin alpha 1 (ZADAXIN, SciClone Pharmaceuticals Inc.)

Immunosupressants: sirolimus (RAPAMUNE, Wyeth)

Interleukins: (IL-I, IL-3, IL-4, IL-5, IL-6, IL-IO, IL-Il, IL-12), LIF, TGF-beta, TNF- alpha) and other low molecular weight factors (e.g. AcSDKP, pEEDCK, thymic hormones, and minicytokines)

Interferon Enhancers: EMZ702 (Transition Therapeutics)

IRES inhibitors: VGX-410C (VGX Pharma)

Monoclonal and Polyclonal antibodies: XTL-6865 (XTL), HuMax-HepC (Genmab), Hepatitis C Immune Globin (human) (CIV ACER, Nabi Biopharmceuticals) Nucleoside analogues: Lamivudine (EPIVIR, 3TC, GlaxoSmithKline), MK-0608 (Merck), zalcitabine (HIVID, Roche US Pharmaceuticals), ribavirin (including COPEGUS (Roche), REBETOL (Schering), VILONA (ICN Pharmaceuticals, and VIRAZOLE (ICN Pharmaceuticals), and viramidine (Valeant Pharmaceuticals), an amidine prodrug of ribavirin. Combinations .of nucleoside analogues may also be employed.

Non-nucleoside inhibitors: PSI-6130 (Roche/ Phaπnasset), delaviridine (RESCRIPTOR, Pfizer), and HCV-796 (Viropharm)

P7 protein inhibitor: amantadine (SYMMETREL, Endo Pharmaceuticals, Inc.)

Polymerase inhibitors: NM283 (valopicitabine) (Idenix) and NM 107 (Idenix).

Protease inhibitors: BELN-2061 (Boehringer Ingelheim), GW-433908 (prodrug of Amprenavir, Glaxo/ Vertex), indinavir (CRIXIVAN, Merck), ITMN-191 (Intermune/ Array Biopharma), VX950 (Vertex) and combinations comprising one or more of the foregoing protease inhibitors

RNA interference: SIRNA-034 RNAi (Sirna Therapeutics)

Therapeutic Vaccines: IC41 (Intercell), IMN-0101 (Imnogenetics), GI 5005 (Globeimmune), Chronvac-C (Tripep/ Inovio), ED-002 (Imnogenetics), Hepavaxx C (ViRex Medical)

TNF agonists: adalimumab (HUMIRA, Abbott), entanercept (ENBREL, Amgen and Wyeth), infliximab (REMICADE, Centocor, Inc.)

Tubulin inhibitors: Colchicine

Sphingosine-1 -phosphate receptor modulators: FTΥ720 (Novartis)

TLR agonists: ANA-975 (Anadys Pharmaceuticals), TLR7 agonist (Anadys Pharmaceuticals), CPG10101(Coley), andTLR9 agonists including CPG 7909 (Coley)

Cvclophilin Inhibitors: NIM811 (Novartis) and DEBIO-025 (Debiopharm)

[0207] Patients receiving hepatitis C medications are typically given interferon together with another active agent. Thus methods of treatment and pharmaceutical combinations in which a compound of The invention is provided together with an interferon, such as pegylated interferon alfa 2a, as the additional active agents are included as embodiments. Similarly methods and pharmaceutical combinations in which ribavirin is an additional active agent are provided herein. EXAMPLES ABBREVIATIONS

[0208] The following chemical abbreviations are used in Example 1. Additional abbreviations used in these examples will be familiar to those of skill in the art of organic chemical synthesis.

CDI l,r-Carbonyldiimidazole

DBU Diazabicyclo[5.4.0]undec-7-ene

DCM Dichloromethane

DEEA Nj N-Diisopropylethyl amine

DMF Dimethyl foπnamide

HATU O-(7-azabenotriazol-l-yl)-l,l,353-tetramethyluromum

HBTU O-(lH-Benzotriazol-l-yl) N, N,N',N'-tetramemyluronium hexafluorophosphate

NMM N-methylmoφholine

RCM Ring-closing metathesis

TEA Triethylacetate

TFA Trifluoroacetic acid

EXAMPLE 1. SYNTHESIS OF 1-((2S,4R)-1-((S)-2-TERT-BUTYL-4-OXO-4-(PIPERIDIN-1-

YL)BUTANOYL)-4-(7-METHOXY-2-PHENYLQUINOLIN-4-YLOXY)PYRROLIDINE-2-CARBOXAMIDO)-2-

VINYLCYCLOPROPANECARBOXYLIC ACID

Step 1. Preparation of N-(cyclopropylsulfonyl)-l-(BOC-amino)-2- vinylcyclopropanecarboxamide

Figure imgf000053_0001

[0209] CDI (2.98 g, 18.4 mm, 1.1 eq) is dissolved in ethyl acetate. N-Boc- cyclopropylvinyl acid (3.8 g, 16.7 mm, 1.0 eq), prepared via the procedure given by Beaulieu, P.L. et al. (J. Org. Chem. 70: 5869-79 (2005)) is added to the CDI/ ethyl acetate mixture and stirred at RT until the starting material is consumed. Cyclopropyl sulfonamine (2.2 g, 18.4 mm,

1.1 eq) is added to this mixture followed by DBU (2.1 ml, 20.5 mm, 1.23 eq) and the mixture is stirred at RT for 2 h. Workup and purification by silica gel chromatography provides 2g of compound 2.

Step 2. Preparation of (2S,4R)-tert-butyl 2-(l-(cyclopropylsulfonylcarbamoyl)-2- vinylcyclopropylcarbamoyl)-4-(7-methoxy-2-phenylquinolin-4-yloxy)pyrrolidine-l-carboxylate and (2S,4R)-N-(l-(cyclopropylsulfonylcarbamoyl)-2-vinylcyclopropyl)-4-(7-methoxy-2- pheriylquinolin-4-yloxy)pyrrolidine-2-carboxamide

Figure imgf000054_0001

[0210] Compound 1 (4.3 g, 9.3mmol, 1.1 eq), prepared according to the method given ins WO 02/060926, in DMF is stirred with O-(Benzotriazol-lyl)-N3N5N'3N'-Tetramethyluronium hexafluorophosphate (4.1g,10.5mmol, 1.3eq) for 30 minutes, followed by addition of cyclopropylamine 2 (1.92g, 8.3mmol, l.Oeq) and N-methylmorpholine (2.52g, 25.0mmol,3.0eq). The mixture is stirred over night and the solvent removed under reduced pressure. The resulting residue is diluted with ethyl acetate and washed with saturated aqueous NaHCC>3. The organic solvent is dried over MgSO4 and concentrated under reduced pressure to afford crude 3, which is used for next step without further purification. [0211] Compound 3 in 10 ml dry CH2Cl2 is treated with 5 mL TFA and stirred over night. The solvent is removed and the residue recrystallized from ethyl acetate to afford 4.12 g Compound 4 (61% yield two steps).

Step 3. Preparation of (3S)-3-((2S,4R)-2-(l-(cyclopropylsulfonylcarbamoyl)-2- vixιylcyclopropylcarbamoyl)-4-(7-me1iioxy-2-phenylqtdnolin-4-yloxy)pyrrolidine-l-carbonyl)- 4,4-dimethylpentanoic acid

Figure imgf000056_0001

[0212] The Acid 5 (58mg, 0.25mmol, 1.2eq), prepared via the procedure given by Evans, D.A., et al. (J. Org. Chem. 64: 6411- 6417 (1999)) in 1.2 mL DMF is stirred with 4 (138mg, 0.21mmol), HATU (160mg, 0.42mmol, 2.0eq), and DIEA (0.63mmol, 3.0 eq) overnight. The mixture is subjected to HPLC purification to afford 121mg 6 (77% yield), which is further treated with 0.5 mL TFA in 1.0 mL DCM overnight. The solvent was removed to provide Compound 7 in 100% yield.

Step 4. Preparation of (2S,4R)-l-((S)-2-tert-butyl-4-oxo-4-(piperidin-l-yl)butanoyl)-N-(l- (cyclopropylsulfonyIcarbamoyl)-2-vinylcyclopropyl)-4-(7-methoxy-2-phenylquinolin-4- yloxy)pyrrolidine-2-carboxamide

Figure imgf000056_0002

7 8

[0213] The Acid 7 (0.15mmol) in 1.0 mL DMF is stirred with pepriduie (excess, 0.6mmol, 4eq), HATU (115mg, 0.3mmσl5 2.0eq), and DIEA (0.45mmol, 3.0eq) for 4 hrs. The mixture is subjected to HPLC purification to afford 77.1mg 8.

Step 5. Preparation of (3S)-3-((2S,4R)-2-(l-(ethoxycarbonyl)-2-vinylcyclopropylcarbamoyl)-4- (7-methoxy-2-phenylquinolin-4-yloxy)pyrrolidine- 1 -carbonyl)-4,4-diniethylρentanoic acid

Figure imgf000057_0001

9 10 11

Step 5. Preparation of (3S)-3-((2S,4R)-2-(l-(ethoxycarbonyl)-2-vinylcyclopropylcarbamoyl)-4- (7-methoxy-2-phenylquinolin-4-yloxy)pyrrolidine- 1 -carbonyl)-4,4-dimethylpentanoic acid

[0214] The Acid 5 (105mg, 0.46mmol, 1.2eq) in 1.2 mL DMF is stirred with 9 (202mg, O.38mmol), HATU (290mg, 0.76mmol, 2.0eq), and DIEA (1.2mmol, 3.0eq) overnight. The mixture is subjected to HPLC purification to afford 204.3mg 10 (75% yield), which is further treated with 0.5 mL TFA in 1.0 mL DCM overnight. The solvent is removed to provide 11 in 100% yield.

Figure imgf000057_0002

Step 6. Preparation of final product

[0215] The Acid 11 (30mg, 0.045mmol) in LO mL DMF is stirred with pepridine (0.27mmol, 6eq), HATU (34mg, 0.09mmol, 2.0eq), and DIEA (0.14mmol, 3.0eq) for 2 hrs. The mixture is subjected to HPLC purification to afford 21.2 mg 12 (65% yield), which is hydrolyzed in methanol with 2N NaOH for 6 hrs. The mixture is acidified with 6N HCl and subjected to HPLC purification to afford 7.6 mg 13. EXAMPLE 2. SYNTHESIS OF MACROCYCLIC COMPOUNDS

General Procedures

Procedure 1. DeProtection Reaction (Conversion of N-Boc to amine or t-butyl ester to carboxylic acid)

[0216] TFA (3~4ml) is added to a solution of Boc protected starting material (lmmol) or t-butyl ester in anhydrous DCM (7ml) at room temperature. The reaction is monitored with LC/MS and TLC. After 1~3 hrs, the reaction mixture is evaporated reduced pressure to dryness. The crude product is used for next step reaction without further purification. Procedure 2. Amide formation

[0217] N-methylmorpholine (2mmol) and HBTU (1.2mmol) are added in one portion at room temperature to a solution of acid (lmmol) in anhydrous DMF (10ml). After stirring at room temperature 10 minutes, amine (1 mmol) is added in one portion and then stirred overnight. The reaction mixture is poured into ice-water and extracted with ethyl acetate (100ml). The organic layer is washed with H2O, brine, and dried over anhydrous MgSO4. The residue is filtered and evaporated in vacuum to dryness. The crude product is purified by flash chromatography on silica gel (hexane-ethyl acetate 100:0 to 50:50) to give the desired product. Procedure 3. RCM catalyzed by Grubbs 2nd (CAS Reg. No. 246047-72-3) or Hoveyda-

Grubbs 2nd catalyst (CAS Reg. No. 301224-40-8)

[0218] A mixture of starting material (di-olefin, lmmol), catalyst (5~30mol%) in 1,2- dichloroethane is degassed and heated to 110 0C for 12~24hrs under atmosphere of argon. The reaction is monitored by LC/MS and TLC The reaction mixture is evaporated to dryness under reduced pressure. The crude product is purified by flash chromatography on silica gel (hexane- ethyl acetate 100:0 to 50:50) to give the desired product. Procedure 4. Hydrolysis of esters

[0219] LiOH hydrate (6 equiv.) is added in one portion at room temperature to the solution of ester (lmmol) in THF (5ml), methanol (2.5ml), and water (2.5ml), and then the reaction mixture is stirred overnight. After the reaction is complete (by LC/MS), it is cooled to O0C and acidified to pH~2 and extracted with DCM (20ml x 2). The reaction is dried over MgSO4, filtered, and evaporated to dryness under reduced pressure. The crude product is purified by flash chromatography on silica gel (hexane-ethyl acetate 100:0 to 20:80) to give the desired product.

Scheme 1

Figure imgf000059_0001

Hoveyda-Grubbs 2nd Catalyst 1) TFA/DCM

1,2-DCE 2) HBTU/NMM/DMF piperidine

Figure imgf000059_0002

Figure imgf000059_0003

24

23

Compound 21 is prepared by procedures 1 and 2 from starting material 14 and amino acid 20.

MS (M++!) 754.

Compound 22 is prepared by procedure step 3. MS (M++!) 726.

Compound 23 is prepared by procedures 1 and 2. MS (M++!) 737. Compound 24 is prepared by procedure 4. MS (M++!) 709.

Scheme 2. Synthesis of Compounds 34 and 35

Figure imgf000060_0001

34 35

Compound 29 is prepared by procedure 4 from starting material 28. Compound 30 is prepared by procedure set forth in step 2 with starting material 29. Compound 31 is prepared by procedure set forth in steps 1 and 2 with starting material 30. Compound 33 is prepared by procedure set forth in step 4 with starting material 28 and 32. Compounds 34 and 35 are prepared by the procedure set forth in step 3. After RCM, the reaction mixture is separated by prep-TLC (hexane -ethyl acetate 1 : 1) to afford compounds 34 and 35. MS (MΗ-1) = 812 Preparation of intermediates 20 and 32

Figure imgf000061_0001

Step 4

Figure imgf000061_0002

Step 1. 8-nonenoic acid (1.56g, lOmmol) is placed in a 100ml flask, anhydrous ether (35ml) is added under N2, cooled to O0C, TEA (1.6g, 16mmol) is added, followed by pivaloyl chloride (1.26g, 10.5mmol) dropwise. The ice-bath is removed and the reaction mixture is stirred at room temperature for lhr. The resulting suspension is cooled to O0C and filtered into a 250 ml flask under N2 (washed twice with anhydrous ether 10ml x 2). The filtrate is cooled to -78°C and diluted with anhydrous THF (25ml).

[0220] A few crystals of 1,10-phenathroline are added 0 a solution of (S)(-)-4-benzyl-2- oxazolidinone in THF (25ml). The solution is cooled to -780C and a solution of M-BuLi (1.6M in hexane, 6.5ml, 10.4mmol) is added dropwise until the red color persists for 10 min. This solution is added to the above cooled mixed anhydride solution at -78°C over 20 min via cannula. The resulting mixture is stirred at -780C for additional 30min, then poured into sat. NH4CI, the organic layer is separated, the aqueous layer is extracted with ether (50 ml, 3X). The combined organic layers are washed with brine and dried over MgSO4, filtered, concentrated in reduced pressure to dryness. The crude product is purified by flash chromatography (hexane-ethyl acetate 100:0-100:20) to give 3.01g of 26 (95%).

Step 2. A solution of 26 (3.01g, 9.6mrnol) in anhydrous THF is cooled to -780C, then 2.0m solution OfNaN(TMS)2 in hexane (5.76ml) was added dropwise over 1 Omin. After 3OmIn, t-Butyl bromoacetate was added dropwise at -78°C. The reaction mixture was stirred at -78 0C for 2 hrs. LC/MS and TLC monitored the reaction. The reaction was quenched with 10% KHSO4 to pH~4~6, extracted with ethyl acetate, organic layer was washed with H2O, brine, dried over MgSO-J, filtered, evaporated in reduced pressure to dryness. The crude product was purified by chromatography on silica gel (hexane -ethyl acetate 100:0-100:20) to give compound 14.

Step 3. H2O2 (50%, 0.9 ml) is added dropwise over 5 min. at 00C, followed by a solution of LiOH (0.2g in 2ml of H2O). The reaction mixture is added to a solution of 27 (1.05g, 2.44 mmol) in THF/H2O (5: 1 , 24 ml). The mixture is stirred at 0 0C for Ih and then quenched by dropwise addition of an aqueous solution of sodium tbiosulphate (10 ml) while keeping the temperature below 2O0C. The mixture is extracted with ethyl acetate (discarded) and the aqueous phase was acidified to pH~2 with solid citric acid and extracted with ethyl acetate. The combined organic phase is washed with brine, dried over anhydrous sodium sulphate and the solvent removed under reduced pressure. The residue is purified by column chromatography on silica gel, eluting with a gradient system of hexane: ethyl acetate (100:0) to 50:50 to afford the desired compound 20 (503 mg).

Step 4. Compound 36 is prepared by procedure 1.

Step 5. Compound 37 is prepared by procedure 2. Step 6. Compound 32 is prepared from 37 by the procedure given in step 3 for the preparation of compound 20.

EXAMPLE 3. ADDITIONAL TERΉARY AMINE SUBSTITUTED PEPTIDES

Figure imgf000063_0001
Figure imgf000064_0001

Figure imgf000065_0001
Figure imgf000066_0001
Figure imgf000067_0001
Figure imgf000068_0001
Figure imgf000069_0001

EXAMPLE 4. ASSAY FOR IDENTIFYING COMPOUNDS WHICH INHIBIT HCV REPLICATION

[0222] Compounds claimed herein are tested for the ability to inhibit viral replication of the Hepatitis C replicon in cultured cells in which the HCV replicon construct has been incorporated. The HCV replicon system was described by Bartenschlager, et. al (Science, 285, pp. 110-113 (1999)). The replicon system is predictive of in vivo anti-HCV activity; compounds that are active in humans uniformly evidence activity in the replicon assay. [0223] In this assay HCV replicon containing cells are treated with different concentrations of the test compound to ascertain the ability of the test compound to suppress replication of the HCV replicon. As a positive control, HCV replicon-containing cells are treated with different concentrations of interferon alpha, a known inhibitor of HCV replication. The replicon assay system includes Neomycin Phosphotransferase (NPT) as a component of the replicon itself in order to detect the transcription of replicon gene products in the host cell. Cells in which the HCV replicon is actively replicating have high levels of NPT; the level of NPT is proportional to HCV replication. Cells in which the HCV replicon is not replicating also have low levels of NPT and thus do not survive when treated with Neomycin. The NPT level of each sample is measured using a captured ELISA.

[0224] A protocol for testing compounds for the ability to inhibit viral replication of the Hepatitis C replicon cultured cells in which the replicon construct has been incorporated, follows. 4 A. HCV Replicon and Replicon Expression

[0225] The HCV genome consists of a single ORP that encodes a 3000 amino acid polyprotein. The ORF is flanked on the 5' side by an untranslated region that serves as an internal ribosome entry site (IRES) and at the 3' side by a highly conserved sequence necessary for viral replication (3'-NTR). The structural proteins, necessary for viral infection, are located near the 5' end of the ORF. The non-structural proteins, designated NS2 to NS5B comprise the remainder of the ORF.

[0226] The HCV replicon contains, 5'-3', the HCV-IRES, the neomycin phosphotransferase (neo) gene, the IRES of encephalomyocarditis virus, which directs translation of HCV sequences NS3 to NS5B, and the 3'-NTR. .The sequence of the HCV replicon has been deposited in GenBank (Accession no. AJ242652).

[0227] The replicon is transfected into Huh-7 cells using standard methods such as electroporation. 4B. Cell Maintenance

[0228] The equipment and materials include, but are not limited to, Huh-7 HCV replicon- containing cells, maintenance media (DMEM (Dulbecco's modified Eagle media) supplemented with 10% FBS, L-glutamine, non-essential amino acids, penicillin (100 units/ml), streptomycin (100 micrograms/ml), and 500 micrograms/ml of Geneticin (G418), screening media (DMEM supplemented with 10% FBS, L-glutamine, non-essential amino acids, penicillin (100 units/ml) and streptomycin (100 πύcrograms/ml)), 96 well tissue culture plates (flat bottom), 96 well plates (U bottom for drug dilution), Interferon alpha for positive control, fixation reagent (such as methanol: acetone), primary antibody (rabbit anti-NPTII), secondary antibody: Eu-Nl 1, and enhancement solution.

[0229] HCV replicon-containing cells support high levels of viral RNA replicon replication when their density is suitable. Over-confluency causes decreased viral RNA replication. Therefore, cells must be kept growing in log phase in the presence of 500 micrograms/ml of G418. Generally, cells should be passed twice a week at 1: 4-6 dilution. Cell maintenance is conducted as follows:

[0230] HCV replicon-containing cells are examined under a microscope to ensure that cells growing well. Cells are rinsed once with PBS and 2 ml trypsin is added. The cell/ trypsin mixture is incubated at 37 0C in a CO2 incubator for 3-5 minutes. After incubation 10 ml of complete media is added to stop the trypsinization reaction. Cells are blown gently, put into a 15 ml tube, and spun at 1200 rpm for 4 minutes. The trypsin/ medium solution is removed. Medium (5 ml) is added and the cells are mixed carefully. The cells are counted.

[0231] The cells are then seeded onto 96- well plates at a density of 6000-7500 cells/100 microliters/ well (6-7.5 x 105 cells/10 ml/plate). The plates are then incubated at 37 0C in a 5% CO2 incubator.

[0232] Cells are examined under a microscope approximated 24 hours after seeding and prior to adding drugs. If counting and dilution were performed correctly, cells are 60-70% confluent and nearly all cells should attach and spread evenly in the well. 4C. Treatment of HCV-replicoή containing cells with Test Compound

[0233] HCV replicon-containing cells are rinsed with once PBS once; 2 mis of trypsin are then added. Cells are incubated at 37°C in a 5% CO2 incubator for 3-5 minutes. 10 mis of complete medium is added to stop the reaction. Cells are blown gently, put into a 15 ml tube, and spun at 1200 rpm for four minutes. The trypsin/medium solution is removed and 5 mis of medium (500 ml DMEM (high glucose)) from BRL catalog #12430-054; 50 mis 10% FBS, 5% Geneticin G418 (50 mg/ml, BRL catalog #10131-035), 5 ml MEM non-essential amino acids (10Ox BRL #11140-050) and 5 ml pen-strep (BRL #15140-148) is added. The cells and media are mixed carefully [0234] Cells are plated with screening medium (500 ml DMEM (BRL #21063-029), 50 ml FBS (BRL #10082-147) and 5 ml MEM non-essential amino acid (BRL #11140-050) at 6000-7500 fcells/100 μl/well of 96 well plate (6-7.5x105 cells/10 ml/plate). Plates are placed into 37° C 5% CO2 incubator overnight. 4D. Assay

[0235] The following morning, drugs (test compounds or interferon alpha) are diluted in 96 well U bottom plates with media or DMSO/media, depending on the final concentration chosen for screening. Generally for 6 concentrations of each test compounds ranging from 10 micromolar to 0.03 micromolar are applied. 100 μl of the test compound dilution is placed in wells of the 96 well plate containing the HCV replicon cells. Media without drug is added to some wells as a negative controls. DMSO is known to affect cell growth. Therefore, if drugs diluted in DMSO are used, all wells, including negative control (media only) and positive control (interferon alpha) wells, must contain the same concentration of DMSO, for single dose screening. The plates are incubated at 37°C in a humidified 5% CO2 environment for three days.

[0236] On day four, the NTPII assay is quantitated. The medium is poured from the plates and the plates are washed once in 200 μl of PBS. The PBS is then decanted and the plates tapped in a paper towel to remove any remaining PBS. Cells are fixed in situ with 100 μl/well of pre-cooled (-20"C) methanol: acetone (1:1) and the plates are placed at -20"C for 30 minutes.

[0237] The fixing solution is poured from the plates and the plates allowed to air-dry completely (approximately one hour). The appearance of the dried cell layer is recorded and the density of the cells in the toxic wells is scored with the naked eye. Alternatively cell viability may be assessed using the MTS assay described below.

[0238] The wells are blocked with 200 μl of blocking solution (10% FBS; 3% NGS in PBS) for 30 minutes at room temperature. The blocking solution is removed and 100 μl of rabbit anti-NPTII diluted 1:1000 in blocking solution is added to each well. The plates are then incubated 45-60 minutes at room temperature. After incubation, wells are washed six times with PBS-0.05% Tween-20 solution. 100 μl of 1 : 15,000 diluted Europium (EU)-conjugated goat anti- rabbit in blocking buffer is added to each well and incubated at room temperature for 30-45 minutes. The plates are washed again and 100 μl of enhancement solution (Perkin Elmer #4001- 0010) is added to each well. Each plate is shaken (approx. 30 rpm) in a plate shaker for three minutes. 95 μl is transferred from each well to a black plate; the EU signal is quantitated in a Perkin-Elmer VICTOR plate reader (EU-Lance).

[0239] Compounds shown in Example 3 have been tested in this assay. Those with one "*" in the EC50 column have an EC50 greater than 10 micromolar, those with two 's (**) have an EC50 of greater than 1 micromolar but less than 10 micromolar, and compounds with three 's (***) have EC50 values of 100 nanomolar or less. EXAMPLE 5. CYTOTOXICITY ASSAYS

[0240] To insure that the decrease in replicon replication is due to compound activity against the HCV replicon rather than nonspecific toxicity assays are used to quantitate compound cytotoxicity. 5A. Cellular protein albumin assay for cytotoxicity

[0241] Cellular protein albumin measurements provide one marker of cytotoxicity. The protein levels obtained from cellular albumin assays may also be used to provide a normalization reference for antiviral activity of compounds. In the protein albumin assay HCV replicon- containing cells are treated for three days with different concentrations of helioxanthin; a compound that is known to be cytotoxic at high concentrations. The cells are lysed and the cell lysate used to bind plate-bound goat anti-albumin antibody at room temperature (250C to 28 0C) for 3 hours. The plate is then washed 6 times with IX PBS. After washing away the unbound proteins, mouse monoclonal anti-human serum albumin is applied to bind the albumin on the plate. The complex is then detected using phosphatase-labeled anti-mouse IgG as a second antibody. 5B. MTS Assay for Cytotoxicity

[0242] Cell viability may also be determined by CELLTITER 96 AQUEOUS ONE Solution Cell Proliferation Assay (Promega, Madison WI), a colorimetric assay for deteπnining the number of viable cells, hi this method, before fixing the cells, 10-20 ul MTS reagent is added to each well according to manufacturer's instructions, plates are incubated at 370C and read at OD 490 nm. During the incubation period living cells covert the MTS reagent to a formazan product which absorbs at 490 nm. Thus the 490 nm absorbance is directly proportional to the number of living cells in culture.

[0243] A direct comparison of the Cellular Albumin and MTS methods for deteπnining cytotoxicity may be obtained as follows: Cells are treated with different concentrations of test compound or Helioxanthin for a three day-period. Prior to lysis for detection albumin as described above, the MTS reagent is added according to manufacturer's instruction to each well and incubate at 37 0C and read at OD 490 nm. The cellular albumin quantitation is then performed as described above.

Claims

CLAIMS • What is claimed is:
1. A compound of the formula:
Figure imgf000075_0001
or a pharmaceutically acceptable salt thereof, where represents a double or single covalent bond, and the group
Figure imgf000075_0002
contains 0 or 1 double bonds;
Ri is -NR10Rn,
Figure imgf000075_0003
-SO2Rn, -(C=O)OR12, -O(C=O)Ri2, -ORi2, Or-N(C=O)R12, or
R2 is hydrogen, Cj-Cβalkyl, C3-C7cycloalkyl, heterocycloalkyl, (aryl)Co-C4alkyl, or
Ri and R2 are taken together to form an optionally substituted 5- to 7-membered heterocyclic ring containing 0 or 1 additional N, S, or O atoms, or an optionally substituted 5- to 7- membered heterocyclic ring containing 0 or 1 additional N, S, or O atoms fused to an optionally substituted 5- to 7-membered carbocyclic or heterocyclic ring;
R3, R4, Rs, Re, R7, and Rs are independently (a) hydrogen, halogen, or amino, or
0) Ci-Cealkyl, C2-C6alkenyl, (C3-C7cycloalkyl)C0-C4alkyl, (C3-C7cycloalkenyl)C0- C4alkyl, (heterocycloalkytyCo-Gjalkyl, Cz-Cβalkanoyl, or mono- or di- Ci-Cealkylamino, each of which is optionally substituted; or B-3 and R4 may be joined to form an optionally substituted 3- to 7- membered cycloalkyl ring or an optionally substituted 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O;
R5 and R$ may be joined to form an optionally substituted 3- to 7- membered cycloalkyl ring or an optionally substituted 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O;
R7 and Rg may be joined to form an optionally substituted 3- to 7- membered cycloalkyl ring or an optionally substituted 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O; or
Rs is a C7-C11 saturated or unsaturated hydrocarbon chain that is (i) covalently bound to R7, where R7 is a methylene group or R5 is a C7-Cn saturated or unsaturated hydrocarbon chain that is (ii) covalently bound to an optionally substituted cycloalkyl ring formed by R7 and Rs being joined to from a 3- to 7- membered optionally substituted cycloalkyl ring; and Re is hydrogen, Ci-Cealkyl, or (C3~C7cycloalkyl)Co-C2alkyl;
T is a tetrazole group attached via its carbon atom, or
T is a group of the formula:
R >9 is hydroxyl, amino, -COOH, -NRi0Rn, -ORn, -SR12,
Figure imgf000076_0001
-NR10SO2R11,
-NRi0SONRnRi2, -NRioS02NRnRi2, -(C=O)ORi0, -NRi0(C=O)ORi 1, or -CONR10R11, or
R9 is Ci-Cβalkyl, C2-C6a]kenyl, C2-C6alkanoyl, (C3-C7cycloalkyl)Co-C4alkyl5 (C3-
C7cycloalkenyl)C0-C4alkyl, (C3-C7cycloalkyl)CH2SO2-, (C3-C7CyClOaIlCyI)CH2SO2NRiO-, (heterocycloalkyl)Co-C4alkyl, (aryl)Co-C2alkyl, or (5- to 10-membered heteroaryl)Co- C2alkyl, each of which is optionally substituted, or
R9 is aphosphonate of the formula
Figure imgf000076_0002
where p is 0, 1 , or 2;
R9 is RχXCo-C4alkyl-, where X is -(C=O)NH-, -NH(C=O)- and Rx is aryl or heteroaryl, or R9 is -CH(Rγ)(C3-C7cycloalkyl), -Sθ2CH(Rγ)(C3-C7cycloalkyl), Or -NRi0SO2CH(RY)(C3- C7cycloalkyl), where Rγ is halogen or RY is Ci-Cβalkyl, C2-C6alkanoyl, (C3- C7cycloalkyl)C0-C4alkyl, (C4-C7cycloaIkenyl)Co-C4alkyl, (aryl)C0-C4alkyl, (aryl)Co- C4alkoxy, (heterocycloalkyl)Co-C2alkyl, or (5- to 10-membered heteroaryl)Co-C4alkyl, each of which is optionally substituted;
Rio, Rn, and Rn are independently at each occurrence hydrogen, or
Ci-Cealkyl, C2-C6alkenyl, G2-C6alkynyl, (aryl)C0-C2alkyl, (C3-C7cycloalkyl)C0-C2alkyl, (C3- C7cycloalkenyl)Co-C2alkyl, (heterocycloalkyl)Co-C2aUcyl, or (5- to 10-membered heteroaryl)Co-C2alkyl, each of which is optionally substituted;
R13 is hydrogen or Ci-C2alkyl;
RH and R15 are independently hydrogen, hydroxyl, or Ci-C2alkyl; n is O, 1, or 2;
M is hydrogen, halogen, hydroxyl, Ci-C2alkyl, or Ci-C2alkoxy,
Y is absent, CR18R19, NR20, S, O, -0(C=O)(NR20)-, NH(C=O)(NR20)-, NH(S=O)(NR20)-, or
-O(C=O)-; or
Y is taken together with one of J, L, or M to form a ring;
J is CH2 or J is taken together with Y to form a 3- to 7- membered carbocyclic or heterocyclic ring, which ring is substituted with 0 or 1 or more substituents independently chosen from halogen, hydroxy, amino, cyano, Ci.-C2alkyl, C]-C2alkoxy, CrC∑alkoxy, trifluoromethyl, and trifluoromethoxy; when J is taken together with Y to form a ring Z may be absent;
L is CH2 or L is taken together with Y to form a 3- to 7- membered carbocyclic or heterocyclic ring, which ring is substituted with 0 or 1 or more substituents independently chosen from halogen, hydroxy, amino, cyano, Q-Qjalkyl, Ci-C2alkoxy, d-C-alkoxy, trifluoromethyl, and trifluoromethoxy; when L is taken together with Y to form a ring Z may be absent;
Z is (mono- orbicyclic aryl)Co-C2alkyl or (mono- or bicyclic heteroaryl)Co-C2alkyl, each of which Z is substituted with
0 or 1 or more substituents independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, -SO2NRnR12, -(C=O)NRi1Ri2, -NRn(C=O)Ri2, Ci-C4alkyl, C2- C4alkanoyl, Ci-C4alkoxy, Ci-e4alkylthio, mono- and di-Ci-C4alkylamino, Ci-
C4alkylester, Ci-C2haloalkyl, and Ci-C2haloalkoxy, and
0 or 1 (Cs-Cycycloalky^Q^alkyl, (phenyl)C0-C2alkyl, (phenyl)Co-C2alkoxy, (5- or 6- membered heteroaryl)Co-C2alkyl, (5- or 6-membered het6roaryl)Co-C2alkoxy, naphthyl, indanyl, (5- or 6-membered heterocycloalkyI)Co-C2alkyl, or 9- or 10-membered bicyclic heteroaryl, each of which is substituted with 0, 1, or 2 substituents independently chosen from:
(c) halogen, hydroxyl, amino, cyano, nitro, -COOH, -CONH2, CH3(C=O)NH-, =NOH, Ci-C4alkyl, Ci-C4alkoxy, Ci-GΛydroxyalkyl, mono- and di-Ci-C4alkylamino, - NR8SO2Rn, -C(O)ORu, -NR8CORu, -NR8C(O)ORn, trifluoromethyl, and trifluoromethoxy, and
(d) phenyl and 5- or 6-membered heteroaryl, each of which is substituted with O or 1 or more of halogen, hydroxyl, Ci-C4alkyl, and Ci-C2alkoxy;
Ri6 represents O to 4 substituents is independently chosen at from halogen, Ci-C2alkyl, and Ci-
C2alkoxy, Ri8 and R^ are independently hydrogen, hydroxyl, halogen, Ci-C2alkyl, Ci-C2alkoxy, Ci-
C2haloalkyl, or Ci-C∑haloalkoxy; and R20 is hydrogen, Ci-C2alkyl, Ci-C∑haloalkyl, or Ci-C2haloalkoxy.
2. A compound or salt of Claim 1 , wherein
Ri and R2 are joined to form a 5- to 7- membered heterocyloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, O, and S which ring is optionally fused to a phenyl or 5- or 6- membered heteroaryl to form a bicyclic ring system, each of which 5- to 7- membered heterocycloalkyl ring or bicyclic ring system is optionally substituted.
3. A compound or salt of Claim 2, wherein
Ri and R2 are joined to form a pyrrolidine, piperidine, or piperazine ring or a piperazine ring fused to a phenyl, each of which is optionally substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, amino, CONH2, -COOH, Ci-C2alkyl, and Ci-C^alkoxy.
4. A compound of Claim 1 in which Ri is Ci-C4O(C=O)-, C1-C4(C=O)-
Figure imgf000079_0001
5. A compound or salt of Claim 4, wherein Rs is Ci-Cβalkyl or C3-C7cycloalkyl.
6. A compound or salt of Claim 4, wherein Ra is hydrogen.
7. A compound or salt of any one of Claims 1 to 6, wherein R3 and R4 are independently
(a) hydrogen, or
(b) Ci-C4alkyl or (C3-C7cycloalkyl)Co-C4alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, CrGtalkyl, C2-C4alkanoyl, Ci-C4alkoxy, C1-C4BHCyIIhJo, mono- and di-Ci- C4alkylamino, Ci-Cahaloalkyl, and Ci-Cahaloalkoxy.
8. A compound or salt of Claim 7, wherein
R3 and R4 are independently hydrogen, Ci-C4alkyl, or (C3-C7cycloalkyl)Co-C4alkyl.
9. A compound or salt of Claim 8, wherein R3 and R4 are independently hydrogen or methyl.
10. A compound or salt of any one of Claims 1 to 6, wherein
R3 and R4 are joined to form a 3- to 7- membered cycloalkyl ring or 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O, each of which ring is substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, amino, cyano, vinyl, Ci-C2alkyl, Ci-C2alkoxy, trifluoromethyl, and trifluoromethoxy.
11. A compound or salt of Claim 10, wherein
R.3 and R4 are joined to form a 3- to 7- tnembered cycloalkyl ring or 5- to 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O, each of which ring is substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Q-Caalkoxy.
12. A compound or salt of any one of Claims 1 to 11 , wherein Rs and R$ are independently
(a) hydrogen, or
(b) Ci-C4alkyl or (C3-C6cycloalkyl)Co-C4alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Cj-C4alkyl, C2-C4alkanoyl, Ci-C4alkoxy, Ci-C4alkylthio, mono- and di-Ci- C4alkylamino, Ci-Chaloalkyl, and Ci-C2haloalkoxy.
13. A compound or salt of Claim 12, wherein
Rs and Re are independently hydrogen, Ci-C4alkyl, or (C3-C7cycloalkyl)Co-C4alkyl.
14. A compound or salt of Claim 13, wherein Rs and Rή are independently hydrogen or methyl.
15. A compound or salt of any one of Claims 1 to 11 , wherein
Rs and Re are joined to form a 3- to 7- membered cycloalkyl ring or 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O, each of which ring is substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, amino, cyano, vinyl, Ci-^alkyl, Ci-C2alkoxy, trifiuoromethyl, and trifluoromethoxy.
16. A compound or salt of Claim 15, wherein
Rs and Re are joined to form a 3- to 7- membered cycloalkyl ring or 5- to 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O, each of which ring is substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-C2alkoxy.
17. A compound or salt of any one of Claims 1 to 16, wherein R.7 and R8 are independently
(a) hydrogen, or
(b) Ci-C4alkyl or (C3-C7cycloalkyl)Co-C4alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl, Ci-C4alkoxy5 Ci-C4alkylthio, mono- and di-d- C4alkylamino, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
18. A compound or salt of Claim 17, wherein
R7 and R8 are independently hydrogen, Ci-C4alkyl, or (C3-C7cycloalkyl)Co-C4alkyl.
19. A compound or salt of Claim 18, wherein R7 and Rs are independently hydrogen or methyl.
20. A compound or salt of any one of Claims 1 to 16, wherein
R7 and Re are joined to form a 3- to 7- membered cycloalkyl ring or 3- to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O, each of which ring is substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, amino, cyano, vinyl, Ci-Cjalkyl, Ci-C2alkoxy, trifluoromethyl, and trifluoromethoxy.
21. A compound or salt of Claim 20, wherein
R7 and Rs are joined to form a 3- to 7- membered cycloalkyl ring or 5- to 6-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O, each of which ring is substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-C2alkoxy.
22. A compound or salt of any one of Claims 1 to 6 wherein R.3, R4, and Rg, are independently hydrogen or methyl;
Rs is Ci-C6alkyl, C2-C6alkenyl, (C3-C7cycloalkyl)Co-C4alkyl, (C3-C7cycloaIkenyl)Co-C4alkyl5 (heterocycloalkyl)Co-C4alkyl, Ca-Cβalkanoyl, or mono- or di- Ci-Cβalkylarnino; and
R7 and Rs are joined to form an optionally substituted 3- to 7- membered cycloalkyl ring or an optionally substituted 3— to 7-membered heterocycloalkyl ring containing 1 or 2 heteroatoms independently chosen from N, S, and O.
23. A compound or salt of Claim- 19 , wherein
R5 is Ci-Cgalkyl or (C3-C7cycloalkyl)Co-C4alkyl; and
R7 and Rg are joined to form a cyclopropyl ring, which is unsubstituted or substituted with 1 or 2
Ci-C6alkyl or C2-C6alkenyl.
24. A compound or salt of Claim 20, of the formula:
Figure imgf000083_0001
25. A compound or salt of any one of Claims 1 to 6, wherein R.3, R4, Re, and Rs are independently hydrogen or methyl; and
Rs is a C7-C11 saturated or unsaturated hydrocarbon chain that is covalently bound to Rη, where R7 is a methylene group.
26. A compound or salt of Claim 25, of the formula
Figure imgf000084_0001
where D is an alkyl or alkenyl group having 6 to 10 carbon atoms.
27. A compound or salt of Claim 26, of the formula
Figure imgf000084_0002
28. A compound or salt of any one of Claims 1 to 6, wherein
R3, R4, and Re are independently hydrogen or methyl; and
Rs is a C7-C11 saturated or unsaturated hydrocarbon chain that is covalently bound to an optionally substituted cycloalkyl ring formed by R7 and Rs being joined to from a 3- to 7- membered optionally substituted cycloalkyl ring.
29. A compound or salt of Claim 28, of the formula
Figure imgf000085_0001
where D is an alkyl or alkenyl group having 6 to 10 carbon atoms.
30. A compound or salt of Claim 29, of the formula
Figure imgf000085_0002
31. A compound or salt of any one of Claims 1 to 30, wherein
T is a group of the formula ' R9 ; and
R9 is hydroxyl, amino, -COOH, -NRi0Rn, -OR12, -SRn,
Figure imgf000085_0003
-NR10SO2RiI,
-NRiOSONRnR12, -NRioS02NRnRi2, -(C=O)OR10, -NRi0(C=O)ORi h or-CONRioRn-
32. A compound or salt of Claim 31, wherein R9 is -NR1OSO2Rn..
33. A compound or salt of Claim 32 wherein R10 is hydrogen or methyl and Ri 1 is cyclopropyl.
34. A compound or salt of Claim 31 , wherein
R9 is hydroxyl, amino, -COOH, -NRi0Rn, -ORi2, -NRIOSO2RII, -(C=O)ORI0, or -CONRioRii-
35. A compound or salt of any one of Claims 1 to 30, wherein
T is a group of the formula
Figure imgf000086_0001
and
R? is Ci-C6alkyl, C2-C6alkenyl, C2-C6alkanoyl, (C3-C7cycloalkyl)Co-C4aIkyl, (C3-
C7cycloalkenyl)Co-C4alkyl, (heterocycloalkyl)Co-C4alkyl, (aryl)C0-C2alkyl, or (5- to 10- membered heteroaryl)Co-C2alkyl, each of which is substituted with 0 or 1 or more substituents independently chosen from halogen, hydroxyl, amino, cyano, oxo -COOH, -CONH2, oxo, Ci-C4alkyl, Ci-C4alkoxy, C2-C4alkanoyl, Ci-C4alkylthio, mono- and di- Ci-C4alkylamino, Ci-C4alkylester, mono- and di- Ci-C4alkylcarboxamide, Ci- C2haloalkyl, and Q-Czhaloalkoxy.
36. A compound or salt of Claim 35, wherein
R9 is Ci-Cealkyl, C2-C6alkenyl, C2-C6alkanoyl, (C3-C7cycloalkyl)C0-C4alkyl, (C3-
C7cycloalkenyl)C0-C4alkyl, φeterocycloalkyl)Co-C4alkyl, (aryl)C0-C2alkyl, or (5- to 10- membered heteroaryl)Co-C2alkyl each of which is substituted with 0 or 1 or more substituents independently chosen from halogen, hydroxyl, amino, cyano, oxo -COOH, -CONH2, Ci-Gjalkyl, Ci-C4alkoxy, mono- and
Figure imgf000086_0002
and Ci-C2haloalkoxy.
37. A compound or salt of any one of Claims 1 to 30, wherein R9 is a phosphonate of the formula
Figure imgf000086_0003
where p is 1 or 2.
38. A compound or salt of any one of Claims 1 to 30, wherein:
R9 is RxXCi-C4alkyl-, where X is -(C=O)NH-, -NH(C=O)- and Rx is phenyl or pyridyl.
39. A compound or salt of any one of Claims 1 to 30, wherein:
R9 is -CH(Rγ)(C3-C7cycloalkyl), -SO2CH(Rγ)(C3-C7cycloalkyl), Or-NRi0SO2CH(RY)(C3-
C7cycloalkyl), where
RY is halogen, or
RY is Ci-C2alkyl, C2-C6alkanoyl, (C3-C7cycloalkyl)C0-C2alkyl, (ρhenyl)C0-C4alkyl, (phenyl)C0- C4alkoxy, (heterocycloalkytyCo^alkyl, or (5- to 10-memberedheteroaryl)Co-C4alkyl, each of which is substituted with 0 or 1 or more substituents independently chosen from halogen, hydroxyl, amino, cyano, oxo -COOH, -CONH2, oxo, Ci-C4alkyl, Ci-C4alkoxy, mono- and di- Ci-C4alkylamino, Ci-C2haloalkyl, and Ci-C2haloalkoxy.
40. A compound of any one of Claims 1 to 39 wherein
Rio, RH, and Ru are independently Ci -Cβalkyl, Cz-Cβalkenyl, Ca-Cβalkynyl, (C3- C7cycloalkyl)Co-C4alkyl, (heterocycloalkyl)Co-C4alkyl, (phenyl)Co-C2alkyl, (naphthyl)C0- C2alkyl, or (5- to 10-membered heteroaryl)Co-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, amino, cyano, oxo -COOH, -CONH2, oxo, Ci-C4alkyl, Ci-C4alkoxy, C2-C4alkanoyl, Ci-C4alkylthio, mono- and di- Ci-C4alkylamino, Ci-C4alkylester, mono- and di- Ci-C4alkylcarboxamide, Ci-Chaloalkyl, and Ci-C2haloalkoxy.
41. A compound or salt of Claim 40, wherein Rio, Rn, and RJ2 are independently hydrogen, or
Ci-Cealkyl, C∑-Cealkenyl, C2-C6alkynyl, (C3-C7cycloalkyl)Co-C2alkyl, (heterocycloalkyl)Co- C2alkyl, (phenyl)Co-C2alkyl, or (5- to 6-membered monocyclic heteroaryl)Co-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, oxo, Ci-C2alkyl, Ci-C2alkoxy, trifiuoromethyl, and trifluoromethoxy.
42. A compound or salt of Claim 40, wherein Rio, Rn, and Rj2 are independently hydrogen or Ci-Cβalkyl.
43. A compound or salt of any one of Claims 1 to 42 wherein n is 0; and
Y is absent, CH2, O, or -O(C=O)-.
44. A compound or salt of Claim 40 wherein n is 0 and Y is O.
45. A compound or salt of any one of Claims 1 to 42 wherein n is 1;
Y is absent, CH2, O, or -O(C=O)-; and
Ri 8 and Ri 9 are independently hydrogen or methyl.
46. A compound or salt of any one of Claims 1 to 45 wherein M is hydrogen.
47. A compound or salt of any one of Claims 1 to 46, wherein J and L are both CH2.
48. A compound or salt of any one of Claim 1 to 47 wherein
Z is 1-naphthyl, 2-napthyl,
Figure imgf000089_0001
Figure imgf000089_0002
Figure imgf000089_0004
Figure imgf000089_0003
Figure imgf000089_0005
Figure imgf000090_0001
Figure imgf000090_0004
Figure imgf000090_0005
Figure imgf000090_0002
Figure imgf000090_0006
Figure imgf000090_0007
Figure imgf000090_0008
Figure imgf000090_0003
Figure imgf000090_0009
49. A compound or salt of any one of Claims 1 to 47, wherein Z is a group of the formula
Figure imgf000091_0001
wherein
X1, X2, X3, X4, and X5 are independently N or CH and no more than two of Xi — X5 are N;
Gi, G2, G3, and G4 are independently CH2, O, S, orNR26, wherein no more than two of Gi to G4 are other than hydrogen; R21 represents from 0 to 3 groups independently chosen from halogen, hydroxyl, amino, cyano,
-CONH2, -COOH, CrC-jalkyl, C2-C4alkanoyl, C1-C4alkoxy, C1-C4aUcylthio, mono- and di-Ci-C4alkylamino, Ci-C2haloalkyl, and Ci-C2haloalkoxy, R22 is hydrogen, halogen, hydroxyl, amino, cyano, -CONH2, -COOH5 Ci-C4alkyl, C2-C4alkanoyl,
Cι-C4alkoxy, Ci-C4alkylthio, mono- and di-Ci-C4alkylamino, Ci-C4alkylester, Ci-
Cahaloalkyl, and Ci-C2haloalkoxy, or R22 is (C3-C7cycloalkyl)Co-C2alkyl, (phenyl)C0-C2alkyl, (phenyl) C0-C2alkoxy, (5- or 6- membered heteroaryl)Co-C2alkyl, (5- or 6-membered heteroaryl)Co-C2alkoxy, naphthyl, indanyl, (5- or 6-membered heterocycloalkyl)Co-C2alkyl, or 9- or 10 membered bicyclio heteroaryl, each of which is substituted with 0, 1, or 2 substituents independently chosen
(c) halogen, hydroxyl, amino, cyano, nitro, -COOH, -CONH2, CH3(C=O)NH-, Cr C4alkyl, Ci-C4alkoxy, Ci-C4hydroxyalkyl, mono- and di-CrCΛalkylamino, -NRsSOaRn, -C(O)ORn, -NR8CORn, -NR8C(O)ORn, trifluoromethyl, trifluoromethoxy, and
(d) phenyl and 5- or 6-membered heteroaryl, each of which is substituted with 0 or 1 or more of halogen, hydroxyl, Ci-C4alkyl, Ci-C2alkoxy;
R23 is 0 to 2 substituents independently chosen from halogen, hydroxyl, Ci-C2alkyl, and Ci-
C2alkoxy; and R24 is independently chosen at each occurrence from hydrogen and Ci-Cϊalkyl.
50. A compound or salt of Claim 49, wherein R22 is
Figure imgf000093_0001
-OCH2CH3.
51. A compound or salt of Claim 49, where Z is a group of the formula
Figure imgf000094_0001
wherein
Xi, X2, X3, and X4, are independently N or CH and no more than two of X1-X4 are N;
R21 represents from 0 to 3 groups independently chosen from halogen, hydroxyl, amirR), cyano,
-CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl, Ci-C4alkoxy, Q-C+alkylthio, mono- and di-Ci-C4alkylammo, Ci-C2haloalkyl, and Q-Chaloalkoxy, R22 is hydrogen, halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl,
Ci-C4alkoxy, Ci-C4alkylthio, mono- and di-Ci-C4alkylamino, Cj-C4alkylester, Ci-
C2haloalkyl, and Ci-C∑haloalkoxy, or R22 is (C3-C7cycloalkyl)CoC2alkyl, (phenyl)Co-C2alkyl, (phenyl)Co-C2alkoxy, (5- or 6-membered heteroaryOCo-Calkyl, (5- or 6-membered heteroaryl)Co-C2alkoxy, naphthyl, indanyl, (5- or 6-membered heterocycloalkyl)CoC2alkyl, or 9- or 10 membered bicyclic heteroaryl, each of which is substituted with 0, 1, or 2 substituents independently chosen from
(c) halogen, hydroxyl, amino, cyano, nitro, -COOH, -CONH2, CH3(C=O)NH-, Ci-C4alkyl, C1-
C4alkoxy, Ci-C4hydroxyalkyl, mono- and di-Ci-C4alkylamino, -NRgSO2Rn, -C(O)ORu, -NR8CORu, -NR8C(O)ORn, trifluoromethyl, and trifluoromethoxy, and
(d) phenyl and 5- or 6-membered heteroaryl, each of which is substituted with O or 1 or more of halogen, hydroxyl, Ci-C4alkyl, d-Caalkoxy.
52. A compound or salt of Claim 51 , wherein Z is a group of the formula
Figure imgf000094_0002
53. A compound or salt of Claim 51 , where Z is a quinoline of the formula
Figure imgf000095_0001
54. A compound or salt of Claim 53, wherein
R21 represents a substituent at the 7-position of the quinoline, and 0 to 2 additional substituents independently chosen from halogen, hydroxy], amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl, Ci-C4alkoxy, mono- and di-Q- C4alkylamino, Ci-C2haloalkyl, and Cj-Cahaloalkoxy; and
R22 is (ρhenyl)Co-C2alkyl or (pyridyl)C0-C2alkyl, each of which is substituted with 0, 1, or 2 substituents independently chosen from halogen, hydroxyl, amino, cyano, -COOH, -CONH2, Ci-C4alkyl, Ci-C4alkoxy, mono- and di-Ci-C4alkylamino, trifluoromethyl, and trifluoromethoxy.
55. A compound or salt of Claim 53, wherein
R21 is a methoxy or ethoxy substituent at the 7-ρosition of the quinoline and R22 is phenyl or pyridyl.
56. A compound or salt of any one of Claims 1 to 47 wherein n is 0, Z is absent, and Y and M are taken together to form a ring, so that
Figure imgf000096_0001
is a group for the formula:
Figure imgf000096_0002
GJ, G2, G3, G4, and G5 are independently CH2, O, S, or NR22; wherein no more than two of Gi,
G2, G3, GA, and G5 are other than Ctfe; R21 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci-Calkyl, and Ci-
Caalkoxy;
R22 is independently chosen at each occurrence from hydrogen and methyl; and R23 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci-Caalkyl, and Ci-
C2alkoxy.
57. A compound or salt of Claim 1 to 47 wherein n is 0, M is hydrogen, Z is absent, and Y and J are taken together to form a ring, so that
Figure imgf000097_0001
is a group for the formula:
Figure imgf000097_0002
Gj, G2, G3, and G4 are independently CH2, O, S, or NR22; wherein no more than two of Gi, G2,
G3, and G4 are other than CEfe; R21 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci-C2alkyl, and Ci-
C2alkoxy; R22 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci-C2alkyl, and Q-
C2alkoxy; and R23 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci-C2alkyl, and Ci-
C2alkoxy.
58. A compound or salt of Claim 57 wherein
Figure imgf000098_0001
is a group for the formula:
Figure imgf000098_0002
59. A compound or salt of any one of Claims 1 to 47 wherein n is 0, Z is absent, and Y and L are taken together to form a ring, so that
Figure imgf000099_0001
is a group for the formula:
Figure imgf000099_0002
where: Gj, G2, G3, and G4 are independently CH2, O, S, OrNR22; wherein no more than two OfG1, G2,
G3, and G4 are other than CH2; Qi and Q2 are independently CH or N; R21 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci-Czalkyl, and Cj-
Caalkoxy; R22 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci-Czallcyl, and Cj-
Caalkoxy; and R23 is 0 to 2 substituents independently chosen from halogen, hydroxy, Ci-C^alkyl, and Cj-
C2alkoxy.
60. A compound or salt of Claim 59 wherein
Figure imgf000100_0001
is a group for the formula:
Figure imgf000100_0002
Figure imgf000101_0001
Figure imgf000102_0001
61. A compound or salt of Claim 1 , of the formula
Figure imgf000103_0001
wherein
Ri and R2 are joined to form a pyrrolidine, piperidine, or piperazine ring or a piperazine ring fused to a phenyl, each of which is optionally substituted with 0 to 2 substituents independently chosen from halogen, hydroxyl, amino, CONH2, Ci-C4alkyl(C=O)-COOH, Ci-C2alkyl, and Ci-C2alkoxy;
R3, R4, Re, and Rg are independently chosen from hydrogen, Ci-C4alkyl, and (C3- C7cycloalkyl)C0-C2alkyl;
R9 is hydroxyl, amino, -COOH, -NRioRπ, -ORn, -NR10SO2R1U -(C=O)OR10, or -CONRi0Rn;
Rio, Rn > and R12 are independently hydrogen, or
Ci-C6alkyl, C2-C6alkenyl, C2~C6alkynyl, (C3-C7cycloalkyl)Co-C2alkyl, (heterocycloalkyl)Co- C2alkyl5 (phenyl)Co-C2alkyl, or (5- to 6-membered monocyclic heteroaryl)Co-C2alkyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxyl, oxo, Ci-C2alkyl, C1-C2alkoxy, trifluoromethyl, and trifluoromethoxy;
R16 is 0 to 2 substituents independently chosen from halogen,
Figure imgf000103_0002
and Cj-C2alkoxy;
M is hydrogen or methyl; and
Z is a quinoline of the formula
Figure imgf000103_0003
wherein
R21 represents a substituent at the 7-position of the quinoline, and 0 to 2 additional substituents independently chosen from halogen, hydroxyl, amino, cyano, -CONH2, -COOH, Ci-C4alkyl, C2-C4alkanoyl, Ci-C4alkoxy, mono- and di-Ci- C4alkylamiαo, Ci-C2haloalkyl, and Ci-C2haloalkoxy; and
R22 is (phenyl)Co -C^alkyl or (pyridyl)Co-C2alkyl, each of which is substituted with 0, 1, or 2 substituents independently chosen from halogen, hydroxyl, amino, cyano, -COOH, -CONH2, Ci-C4aikyl, Ci-C4alkoxy, mono- and di-Ci-C4alkylamino, tiifluoromethyl, and trifluoromethoxy.
62. A pharmaceutical composition comprising a therapeutically effective amount of one or more compounds or salts of any one of Claims 1 to 61 and at least one pharmaceutically acceptable carrier.
63. The pharmaceutical composition of Claim 62 additionally comprising a second active agent.
64. The pharmaceutical composition of Claim 63 wherein second active agent is ribavarin.
65. The pharmaceutical composition of any one of Claims 62 to 64 additionally comprising at least one interferon or Peg-interferon alpha conjugate.
66. The pharmaceutical composition of any one of Claims 62 to 65, wherein the composition is formulated as an injectable fluid, an aerosol, a cream, a gel, a tablet, a pill, a capsule, a syrup, ophthalmic solution, or a transdermal patch.
67. A package comprising the pharmaceutical composition of any one of Claims 60 to 66 in a container and further comprising instructions for using the composition to treat a patient suffering from Hepatitis C infection.
68. A method of treating or preventing a hepatitis C infection, comprising providing a therapeutically effective amount of one or more compounds of any of Claims 1 to 61 to a patient in need thereof.
69. The method of Claim 66 wherein the therapeutically effective amount is an amount sufficient to significantly decrease the number of HCV antibodies in the patient's blood or serum.
70. A method of inhibiting HCV replication in vivo comprising providing to a patient infected with HCV a concentration of a compound or salt of any of Claims 1 to 61 sufficient to inhibit HCV replicon replication in vitro.
PCT/US2007/016018 2006-07-13 2007-07-13 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication WO2008008502A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US83048806 true 2006-07-13 2006-07-13
US60/830,488 2006-07-13
US94578607 true 2007-06-22 2007-06-22
US60/945,786 2007-06-22

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2009519549A JP5517614B2 (en) 2006-07-13 2007-07-13 4-amino-4-oxobutanoyl peptides as viral replication inhibitor
CA 2657618 CA2657618C (en) 2006-07-13 2007-07-13 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CN 200780026271 CN101506223B (en) 2006-07-13 2007-07-13 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
DK07810457T DK2041156T3 (en) 2006-07-13 2007-07-13 4-amino-4-oxobutanoylpeptider as inhibitors of viral replication
KR20097002894A KR101512477B1 (en) 2006-07-13 2007-07-13 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP20070810457 EP2041156B1 (en) 2006-07-13 2007-07-13 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
ES07810457T ES2448494T3 (en) 2006-07-13 2007-07-13 Peptides of 4-amino-4-oxobutanoilo as inhibitors of viral replication

Publications (1)

Publication Number Publication Date
WO2008008502A1 true true WO2008008502A1 (en) 2008-01-17

Family

ID=38614189

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/016018 WO2008008502A1 (en) 2006-07-13 2007-07-13 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication

Country Status (8)

Country Link
US (4) US7906619B2 (en)
EP (2) EP2374812B1 (en)
JP (1) JP5517614B2 (en)
KR (1) KR101512477B1 (en)
CA (1) CA2657618C (en)
DK (1) DK2041156T3 (en)
ES (1) ES2448494T3 (en)
WO (1) WO2008008502A1 (en)

Cited By (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010059937A1 (en) * 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
WO2010068761A2 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US20100216725A1 (en) * 2008-12-10 2010-08-26 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8420596B2 (en) 2008-09-11 2013-04-16 Abbott Laboratories Macrocyclic hepatitis C serine protease inhibitors
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
WO2014145507A1 (en) * 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
WO2014144087A1 (en) * 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2014152928A3 (en) * 2013-03-14 2015-01-08 Achillion Pharmaceuticals, Inc. Processes for producing sovaprevir
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
JP2015078193A (en) * 2008-02-28 2015-04-23 アッヴィ・インコーポレイテッド Tablet and preparation thereof
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9610317B2 (en) 2006-07-13 2017-04-04 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003007697A (en) * 2001-06-21 2003-01-10 Hitachi Kokusai Electric Inc Method for manufacturing semiconductor device, method and apparatus for processing substrate
KR101294467B1 (en) 2005-07-25 2013-09-09 인터뮨, 인크. Novel macrocyclic inhibitors of hepatitis c virus replication
EP1999129B1 (en) 2005-10-11 2010-12-29 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
KR20090024834A (en) * 2006-07-05 2009-03-09 어레이 바이오파마 인크. Novel inhibitors of hepatitis c virus replication
US8435984B2 (en) * 2007-02-26 2013-05-07 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of HCV replication
EP2177523A1 (en) * 2007-05-03 2010-04-21 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
EP2185524A1 (en) 2007-05-10 2010-05-19 Intermune, Inc. Novel peptide inhibitors of hepatitis c virus replication
JP5574982B2 (en) * 2008-02-04 2014-08-20 イデニク プハルマセウティカルス,インコーポレイテッド Macrocyclic serine protease inhibitor
JP2011519364A (en) * 2008-04-15 2011-07-07 インターミューン・インコーポレーテッド Hepatitis C virus replication of new macrocyclic inhibitors
US20120128628A1 (en) * 2009-02-27 2012-05-24 Porter Steven B COMBINATION OF A NUCLEOSIDE POLYMERASE INHIBITOR WITH A MACROCYCLIC PROTEASE INHIBITOR AND USE THEREOF IN THE TREATMENT OF HEPATITIS C, LIVER FIBROSIS AND IMPAIRED LIVER FUNCTION (as amended)
CA2775697A1 (en) * 2009-09-28 2011-03-31 Intermune, Inc. Cyclic peptide inhibitors of hepatitis c virus replication
US9125904B1 (en) * 2010-05-11 2015-09-08 Achillion Pharmaceuticals, Inc. Biphenyl imidazoles and related compounds useful for treating HCV infections
US8835456B1 (en) 2011-03-18 2014-09-16 Achillion Pharmaceuticals, Inc. NS5A inhibitors useful for treating HCV
JP6198721B2 (en) 2011-05-27 2017-09-20 アキリオン ファーマシューティカルズ,インコーポレーテッド Useful substituted ants fan for treating Hcv infection, cyclophane, Heterafan, heteroaryl fan, hetero - Heterafan and metallocene
CA2909273A1 (en) 2013-04-12 2014-10-16 Achillion Pharmaceuticals, Inc. Deuterated nucleoside prodrugs useful for treating hcv
RU2016124178A (en) 2013-11-18 2017-12-20 Форма Терапеутикс, Инк. Compositions containing benzopiperazinyl, as inhibitors bromodomenov vet

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014436A1 (en) 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
WO2003099316A1 (en) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
US20040002448A1 (en) * 1999-04-06 2004-01-01 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
WO2006007708A1 (en) * 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Hepatitis c inhibitor peptide analogs

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69002950T2 (en) 1989-07-19 1994-01-20 Upjohn Co Peptides with diaminoglycolen as a transition state mimic.
WO1993025574A1 (en) * 1992-06-12 1993-12-23 Pfizer Inc. Inhibitors of angiotensin i chymase(s) including human heart chymase
DK1169339T3 (en) 1999-04-06 2005-01-10 Boehringer Ingelheim Ca Ltd Macrocyclic peptides that inhibit hepatitis C virus NS3 protease
FR2812635B1 (en) 2000-08-01 2002-10-11 Aventis Pharma Sa New heterocyclic compounds, preparation and use as drugs such as anti-bacterial
ES2263687T3 (en) * 2000-11-20 2006-12-16 Bristol-Myers Squibb Company tripeptide inhibitors of hepatitis c.
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
WO2004032827A3 (en) * 2002-05-20 2004-10-14 Jeffrey Allen Campbell Hepatitis c virus inhibitors
US20060199773A1 (en) * 2002-05-20 2006-09-07 Sausker Justin B Crystalline forms of (1R,2S)-N-[(1,1-dimethylethoxy)carbonyl]-3-methyl-L-valyl-(4R)-4-[(6-methoxy-1-isoquinolinyl)oxy]-L-prolyl-1-amino-N-(cyclopropylsulfonyl)-2-ethenyl-cyclopropanecarboxamide, monopotassium salt
RU2315039C9 (en) * 2002-05-20 2014-02-10 Бристол-Маерс Сквибб Компани Hepatitis c virus inhibitors
ES2315568T3 (en) * 2002-05-20 2009-04-01 Bristol-Myers Squibb Company Inhibitors of Hepatitis C virus based cycloalkyl p1 'substituted.
EP1408031A1 (en) 2002-10-09 2004-04-14 3 D Gene Pharma Pyrolidine derivatives useful in treatment of hepatitis C virus infection
JP2007524576A (en) 2003-02-07 2007-08-30 エナンタ ファーマシューティカルズ インコーポレイテッド Macrocyclic c hepatitis serine protease inhibitor
US7601709B2 (en) 2003-02-07 2009-10-13 Enanta Pharmaceuticals, Inc. Macrocyclic hepatitis C serine protease inhibitors
DE602004029866D1 (en) * 2003-03-05 2010-12-16 Boehringer Ingelheim Pharma Peptide analogs having an inhibitory effect on hepatitis c
JP4733023B2 (en) 2003-04-16 2011-07-27 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Macrocyclic isoquinoline peptide inhibitors of hepatitis C virus
US7176208B2 (en) * 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
CA2522577C (en) 2003-05-21 2011-04-26 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor compounds
WO2004113365A3 (en) 2003-06-05 2005-07-21 Enanta Pharm Inc Hepatitis c serine protease tri-peptide inhibitors
RU2412198C2 (en) 2003-07-18 2011-02-20 Вертекс Фармасьютикалз Инкорпорейтед Inhibitors of serine proteases, in particular, hc-3-hc4a protease
CN1856502A (en) 2003-09-22 2006-11-01 贝林格尔.英格海姆国际有限公司 Macrocyclic peptides active against the hepatitis c virus
KR100853579B1 (en) 2003-10-14 2008-08-21 어레이 바이오파마 인크. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7132504B2 (en) 2003-11-12 2006-11-07 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7309708B2 (en) 2003-11-20 2007-12-18 Birstol-Myers Squibb Company Hepatitis C virus inhibitors
US7135462B2 (en) 2003-11-20 2006-11-14 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1697348B1 (en) 2003-12-11 2011-12-28 Abbott Laboratories Hiv protease inhibiting compounds
EP1730167B1 (en) 2004-01-21 2011-01-12 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
ES2336009T3 (en) 2004-01-30 2010-04-07 Medivir Ab Inhibitors ns-3 HCV serine protease.
JP4654239B2 (en) 2004-03-15 2011-03-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Process for the preparation of macrocyclic dipeptides suitable for the treatment of hepatitis C virus infection
WO2005095403A3 (en) 2004-03-30 2005-12-01 Steven W Andrews Macrocyclic compounds as inhibitors of viral replication
WO2006002076B1 (en) 2004-06-15 2006-09-14 Tekelec Us Methods, systems, and computer program products for content-based screening of messaging service messages
CA2571984C (en) 2004-07-16 2012-04-10 Gilead Sciences, Inc. Antiviral compounds
CA2573219C (en) * 2004-07-20 2011-01-18 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor dipeptide analogs
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
JP2008513454A (en) 2004-09-17 2008-05-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング A process for the preparation of macrocyclic hcv protease inhibitors
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
US7323447B2 (en) 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
CA2600367C (en) 2005-03-08 2014-08-12 Boehringer Ingelheim International Gmbh Process for preparing macrocyclic compounds
US7592336B2 (en) 2005-05-10 2009-09-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP1891089B1 (en) 2005-06-02 2014-11-05 Merck Sharp & Dohme Corp. HCV protease inhibitors in combination with food
US7608592B2 (en) 2005-06-30 2009-10-27 Virobay, Inc. HCV inhibitors
US7601686B2 (en) * 2005-07-11 2009-10-13 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2007009109A3 (en) 2005-07-14 2007-06-07 Aesop Cho Antiviral compounds
WO2007009227A1 (en) 2005-07-20 2007-01-25 Boehringer Ingelheim International Gmbh Hepatitis c inhibitor peptide analogs
KR101294467B1 (en) 2005-07-25 2013-09-09 인터뮨, 인크. Novel macrocyclic inhibitors of hepatitis c virus replication
CA2617095C (en) 2005-07-29 2014-05-13 Tibotec Pharmaceuticals Ltd. Macrocylic inhibitors of hepatitis c virus
KR101083631B1 (en) 2005-07-29 2011-11-16 메디비르 아베 Macrocylic inhibitors of hepatitis c virus
DK1934243T3 (en) 2005-09-09 2011-09-05 Boehringer Ingelheim Int Cycling metathesis process for the preparation of macrocyclic peptides
EP1999129B1 (en) 2005-10-11 2010-12-29 Intermune, Inc. Compounds and methods for inhibiting hepatitis c viral replication
US7772183B2 (en) * 2005-10-12 2010-08-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US7741281B2 (en) * 2005-11-03 2010-06-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
ES2448494T3 (en) 2006-07-13 2014-03-14 Achillion Pharmaceuticals, Inc. Peptides of 4-amino-4-oxobutanoilo as inhibitors of viral replication
EP1881002A1 (en) 2006-07-20 2008-01-23 Tibotec Pharmaceuticals Ltd. HCV NS-3 serine protease inhibitors
CA2679563A1 (en) 2007-01-08 2008-07-17 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2008095058A1 (en) 2007-02-01 2008-08-07 Taigen Biotechnology Co. Ltd. Hcv protease inhibitors
US8614180B2 (en) * 2008-12-10 2013-12-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
CN105451718B (en) 2013-03-14 2018-09-28 爱克劳有限公司 Microemulsion local delivery platform
EP2970195B1 (en) 2013-03-14 2017-08-02 Achillion Pharmaceuticals, Inc. Processes for producing sovaprevir
US20140271855A1 (en) 2013-03-15 2014-09-18 Achillion Pharmaceuticals Inc. Sovaprevir tablets
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994014436A1 (en) 1992-12-29 1994-07-07 Abbott Laboratories Retroviral protease inhibiting compounds
US20040002448A1 (en) * 1999-04-06 2004-01-01 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
WO2003099316A1 (en) * 2002-05-20 2003-12-04 Bristol-Myers Squibb Company Heterocyclicsulfonamide hepatitis c virus inhibitors
WO2006007708A1 (en) * 2004-07-20 2006-01-26 Boehringer Engelheim International Gmbh Hepatitis c inhibitor peptide analogs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences, 17th ed.,", 1985, MACK PUBLISHING COMPANY, pages: 1418

Cited By (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9636375B2 (en) 2002-05-20 2017-05-02 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8889871B2 (en) 2002-05-20 2014-11-18 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9227940B2 (en) 2002-05-20 2016-01-05 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9610317B2 (en) 2006-07-13 2017-04-04 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
JP2015078193A (en) * 2008-02-28 2015-04-23 アッヴィ・インコーポレイテッド Tablet and preparation thereof
US8877929B2 (en) 2008-09-04 2014-11-04 Bristol-Myers Squibb Company Process for synthesizing substituted isoquinolines
US9309279B2 (en) 2008-09-11 2016-04-12 Abbvie Inc. Macrocyclic hepatitis C serine protease inhibitors
US8642538B2 (en) 2008-09-11 2014-02-04 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8420596B2 (en) 2008-09-11 2013-04-16 Abbott Laboratories Macrocyclic hepatitis C serine protease inhibitors
WO2010059937A1 (en) * 2008-11-20 2010-05-27 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis c virus
US8445430B2 (en) 2008-11-20 2013-05-21 Achillion Pharmaceuticals, Inc. Cyclic carboxamide compounds and analogues thereof as of hepatitis C virus
JP2012509350A (en) * 2008-11-20 2012-04-19 アキリオン ファーマシューティカルズ,インコーポレーテッド Cyclic carboxamide compound for hepatitis C virus and analogues thereof
KR101762842B1 (en) * 2008-12-10 2017-08-04 아칠리온 파르마세우티칼스 인코포레이티드 New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8614180B2 (en) * 2008-12-10 2013-12-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP2364309A4 (en) * 2008-12-10 2012-08-29 Achillion Pharmaceuticals Inc New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
EP2364310A4 (en) * 2008-12-10 2012-05-16 Achillion Pharmaceuticals Inc 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
EP2364310A2 (en) * 2008-12-10 2011-09-14 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
EP2364309A2 (en) * 2008-12-10 2011-09-14 Achillion Pharmaceuticals, Inc. New 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US20140206604A1 (en) * 2008-12-10 2014-07-24 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US20100216725A1 (en) * 2008-12-10 2010-08-26 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
WO2010068761A2 (en) 2008-12-10 2010-06-17 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptide cyclic analogues, inhibitors of viral replication
US9133115B2 (en) 2008-12-10 2015-09-15 Achillion Pharmaceuticals, Inc. 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
JP2012511587A (en) * 2008-12-10 2012-05-24 アキリオン ファーマシューティカルズ,インコーポレーテッド The new 4-amino-4-oxobutanoyl peptides as inhibitors of viral replication
US8993595B2 (en) 2009-04-08 2015-03-31 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors
US9284307B2 (en) 2009-08-05 2016-03-15 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors
US8937041B2 (en) 2010-12-30 2015-01-20 Abbvie, Inc. Macrocyclic hepatitis C serine protease inhibitors
US8951964B2 (en) 2010-12-30 2015-02-10 Abbvie Inc. Phenanthridine macrocyclic hepatitis C serine protease inhibitors
US9353100B2 (en) 2011-02-10 2016-05-31 Idenix Pharmaceuticals Llc Macrocyclic serine protease inhibitors, pharmaceutical compositions thereof, and their use for treating HCV infections
US9527885B2 (en) 2011-05-05 2016-12-27 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8691757B2 (en) 2011-06-15 2014-04-08 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US8993578B2 (en) 2011-10-21 2015-03-31 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US8969357B2 (en) 2011-10-21 2015-03-03 Abbvie Inc. Methods for treating HCV
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8680106B2 (en) 2011-10-21 2014-03-25 AbbVic Inc. Methods for treating HCV
US8853176B2 (en) 2011-10-21 2014-10-07 Abbvie Inc. Methods for treating HCV
US9452194B2 (en) 2011-10-21 2016-09-27 Abbvie Inc. Methods for treating HCV
US8685984B2 (en) 2011-10-21 2014-04-01 Abbvie Inc. Methods for treating HCV
US8809265B2 (en) 2011-10-21 2014-08-19 Abbvie Inc. Methods for treating HCV
US9499550B2 (en) 2012-10-19 2016-11-22 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9598433B2 (en) 2012-11-02 2017-03-21 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9580463B2 (en) 2013-03-07 2017-02-28 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9481708B2 (en) 2013-03-14 2016-11-01 Achillion Pharmaceuticals, Inc. Process for producing Sovaprevir
US9115175B2 (en) 2013-03-14 2015-08-25 Achillion Pharmaceuticals, Inc. Processes for Producing sovaprevir
WO2014152928A3 (en) * 2013-03-14 2015-01-08 Achillion Pharmaceuticals, Inc. Processes for producing sovaprevir
US9085607B2 (en) 2013-03-15 2015-07-21 Achillion Pharmaceuticals, Inc. ACH-0142684 sodium salt polymorph, composition including the same, and method of manufacture thereof
US9227952B2 (en) 2013-03-15 2016-01-05 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
WO2014144087A1 (en) * 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
WO2014145507A1 (en) * 2013-03-15 2014-09-18 Achillion Pharmaceuticals, Inc. A process for making a 4-amino-4-oxobutanoyl peptide cyclic analogue, an inhibitor of viral replication, and intermediates thereof
US9540346B2 (en) 2013-03-15 2017-01-10 Achillion Pharmaceuticals, Inc. Sovaprevir polymorphs and methods of manufacture thereof
US9744170B2 (en) 2014-01-03 2017-08-29 Abbvie Inc. Solid antiviral dosage forms
US9333204B2 (en) 2014-01-03 2016-05-10 Abbvie Inc. Solid antiviral dosage forms

Also Published As

Publication number Publication date Type
DK2041156T3 (en) 2014-02-24 grant
ES2448494T3 (en) 2014-03-14 grant
EP2374812B1 (en) 2015-04-15 grant
KR101512477B1 (en) 2015-04-15 grant
JP5517614B2 (en) 2014-06-11 grant
EP2041156A1 (en) 2009-04-01 application
US20110070168A1 (en) 2011-03-24 application
US9233136B2 (en) 2016-01-12 grant
US20090048297A1 (en) 2009-02-19 application
US7906619B2 (en) 2011-03-15 grant
US9610317B2 (en) 2017-04-04 grant
EP2374812A2 (en) 2011-10-12 application
EP2374812A3 (en) 2012-05-02 application
CA2657618C (en) 2016-10-11 grant
CA2657618A1 (en) 2008-01-17 application
KR20090029836A (en) 2009-03-23 application
US20140328796A1 (en) 2014-11-06 application
US20160082069A1 (en) 2016-03-24 application
US8785378B2 (en) 2014-07-22 grant
JP2009543784A (en) 2009-12-10 application
EP2041156B1 (en) 2013-11-20 grant

Similar Documents

Publication Publication Date Title
US6294534B1 (en) Spiropiperidine derivatives as melanocortin receptor agonists
US6908901B2 (en) Hepatitis C inhibitor peptide analogs
US7504378B2 (en) Macrocyclic peptides active against the hepatitis C virus
US6919423B2 (en) Hepatitis C inhibitor compound
US20050192212A1 (en) Macrocyclic peptides active against the hepatitis C virus
US20080107623A1 (en) Inhibitors of Hepatitis C Virus
US20060258868A1 (en) Hepatitis c inhibitor peptide analogs
US20080181868A1 (en) Macrocylic oximyl hepatitis c protease inhibitors
US20090041721A1 (en) Arylalkoxyl hepatitis c virus protease inhibitors
US20110218175A1 (en) Antiviral agents
US20040048802A1 (en) Hepatitis C virus inhibitors
US20080038225A1 (en) Triazolyl acyclic hepatitis c serine protease inhibitors
US20050119168A1 (en) Macrocyclic inhibitors of hepatitis C virus NS3-serine protease
US6608027B1 (en) Macrocyclic peptides active against the hepatitis C virus
US20060046965A1 (en) Hepatitis C inhibitor dipeptide analogs
US20090035271A1 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US20090175822A1 (en) C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
US20050080005A1 (en) Macrocyclic peptides active against the hepatitis C virus
WO2006130626A2 (en) Method for modulating activity of hcv protease through use of a novel hcv protease inhibitor to reduce duration of treatment period
WO2000059929A1 (en) Macrocyclic peptides active against the hepatitis c virus
US20050267040A1 (en) Hepatitis C virus inhibitors
EP0479489A2 (en) Tripeptide antithrombotic agents
US20090130059A1 (en) Tetrazolyl macrocyclic hepatitis c serine protease inhibitors
US20090155210A1 (en) Oximyl hcv serine protease inhibitors
WO2009005676A2 (en) Antiviral compounds

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07810457

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10675/DELNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 196256

Country of ref document: IL

ENP Entry into the national phase in:

Ref document number: 2657618

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2009519549

Country of ref document: JP

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 574605

Country of ref document: NZ

Ref document number: 2007272839

Country of ref document: AU

NENP Non-entry into the national phase in:

Ref country code: RU

ENP Entry into the national phase in:

Ref document number: 2007272839

Country of ref document: AU

Date of ref document: 20070713

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 214832

Country of ref document: IL

ENP Entry into the national phase in:

Ref document number: PI0714343

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20090113